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ABSTRACT
Major depression during pregnancy is a risk factor for postpartum depression
(PPD). Medically acceptable treatments for depression during pregnancy and postpartum
are limited and many women are turning to complementary and alternative treatments.
The current project examined whether treatment of major depression during pregnancy
reduced the risk for PPD and explored predictors of PPD in this high-risk sample. One
hundred twenty women were clinically assessed using the Hamilton Rating Scale for
Depression (HRSD17), the Beck Depression Inventory (BDI-II), and the Structured
Clinical Interview for DSM-IV (SCID) at ten weeks, six months, and nine months
postpartum following random assignment to one of three treatments delivered over eight
weeks during pregnancy: active acupuncture, control acupuncture, and control prenatal
massage. Mixed effects analyses revealed that responders to the acute phase of treatment
during pregnancy had significantly lower postpartum BDI-II scores compared to nonresponders. Results also revealed a significant treatment assignment by time interaction
on postpartum HRSD17 scores such that the active acupuncture group maintained
improvement while the control groups worsened postpartum. Exploratory ROC analyses
revealed the following predictors of PPD: discontinuing antidepressant medication, high
intake HRSD17 scores, high late pregnancy HRSD17 scores, low expectations of
treatment, and a history of childhood emotional abuse. Results suggest that successful
treatment of depression during pregnancy may lower the risk of developing PPD.
viii

CHAPTER ONE
INTRODUCTION
Over the past two decades increasing attention has been paid to the complex
phenomenon of postpartum depression. While childbearing is a joyous event in the lives
of women and their families, it is also a particularly vulnerable time for developing or
exacerbating psychiatric illness. Virtually no life event rivals the hormonal,
psychological and social changes associated with pregnancy and childbirth. In fact,
postpartum depression is the most common complication of childbearing. It is estimated
that among the nearly four million births in the United States annually, a half-million
women will endure this disorder every year. Many of these women will be undiagnosed
and untreated.
The consequences of untreated postpartum depression for women, their offspring
and families can be devastating. Postpartum depression may have a deleterious effect on
the woman’s social and personal adjustment, the marital relationship, and the motherinfant interaction (Josefsson, Berg, Nordin, & Sydsjo, 2001). Additional consequences
may include self-harm and suicide (Lindahl, Pearson, & Colpe, 2005). Given the
magnitude of these consequences, it is imperative that health professionals are exhorted
to recognize and treat this problem.
Despite its common occurrence and devastating consequences, postpartum
depression has historically received minimal attention in modern clinical literature,
1
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training, and practice. However, the detection and treatment of postpartum depression
has been recently prioritized as a major public health concern. A United States House
Resolution (H.Res.51) was introduced in 1999 proposing that the National Institutes of
Health further study postpartum psychiatric illness (Lindahl et al., 2005). The resolution
further encouraged health care providers to teach women about the prevalence,
symptoms, and treatment of postpartum depression. Similarly, on the research front, the
Agency for Healthcare Research and Quality recently reported that while much is known
about the risks and vulnerabilities of the postpartum period, there is a significant lack of
substantial high-quality research in this area (Wisner, Chambers, & Sit, 2006). Clearly,
policy makers are encouraging greater surveillance of postpartum depression as well as
better implementation of preventative and treatment methods for childbearing women.
Given the deleterious costs of postpartum depression to individuals and society,
prevention and treatment are large concerns. Toward this end, and as called upon by
governmental agencies, efforts must focus on better understanding this phenomenon. To
date, the largest body of research has focused on individual characteristics that relate to
increased risk for postpartum depression and predictors of postpartum depression. More
recent work has begun to examine viable treatment options as well as measures to prevent
initial onset of mood symptoms in the postpartum period. The present study is designed
to extend this recent body of work by examining the role of treatment during pregnancy
in helping to manage mood symptoms and reduce the likelihood of postpartum
depression.

CHAPTER TWO
REVIEW OF THE RELATED LITERATURE
General Background
Clinicians since Hippocrates have noted an association between the postpartum
period and mood disturbance. As early as 400 B.C. Hippocrates described puerperal
fever in postpartum women and noted symptoms such as agitation, delirium, and mania
(Demand, 1994). An 11th century author similarly pondered the postpartum period
writing that “if the womb is too moist, the brain is filled with water, and the moisture
running over to the eyes, compels them to involuntarily shed tears” (Leopold &
Zoschnick, 1997). Thus, it has long been recognized that childbirth is associated with a
considerable increase in psychological morbidity.
While historical references to postpartum depression were largely anecdotal and
non-empirical, during the 1960’s researchers began to focus on the postpartum period as
an area worth investigating. Converging evidence suggested that women were at
increased risk for the development of depression during the postpartum period
(Paffenbarger & McCabe, 1966; Pugh, Jerath, Schmidt, & Reed, 1963; Ryle, 1961).
However, due to poorly defined or inadequate criteria used to assess and diagnose
depression, there was little consensus on what constituted postpartum depression. While
some measured seeking outpatient psychiatric help (Dalton, 1971), others used selfreported distress as their criterion of depression (Kane, Harmon, Keeler, & Ewing, 1968).
3
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Finally, some did not specify the criteria used to make a depression diagnosis (Tod,
1964).
Extrapolating from the literature, it seems that within the broad spectrum of
postpartum dysphoric mood states, three types of reactions began to emerge in the
1970’s. These included (a) maternity blues, characterized by tearfulness, feelings of
dysphoria, and emotional lability (Pitt, 1973); (b) postpartum depression, similar to an
untreated clinical depression (Meares, Grimwade, & Wood, 1976); and (c) psychotic
depression, often accompanied by delusions (Herzog & Detre, 1976). These working
definitions of postpartum mood states greatly assisted in the differentiation between
normal and abnormal reactions to childbirth.
As a result, a surge of studies in the 1980’s began to investigate the prevalence
and predictors of postpartum depression (Cutrona, 1983; O’Hara, Neunaber, & Zekoski,
1984; Watson, Elliott, Rugg, & Brough, 1984). Additionally, O’Hara (1987) more
explicitly quantified postpartum mood disorders into three categories in ascending level
of severity: blues, depression, and psychosis. Interest in mild and moderate levels of
mood disturbance increased (O’Hara & Zekoski, 1988) as did the timing of the onset of
the mood state (Handley, Dunn, Waldron, & Baker, 1980).
Based on the surge of studies in the 1980’s and converging evidence that women
were at risk for postpartum depression, this linkage entered official psychiatric
nomenclature in 1994. At that time the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition added a postpartum onset specifier within the major depression
diagnosis. DSM-IV defined major depression with postpartum onset as episodes of
depression beginning within four weeks of giving birth (American Psychiatric
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Association, 1994). This time frame corresponds to the rapid hormonal changes posited
to contribute to vulnerability to depression. However, because psychosocial factors also
play a major role in triggering postpartum depression, many researchers have used a
working definition of the postpartum period as lasting up to six months post delivery
(Miller, 2002). These discrepancies in the nosology of perinatal episodes have led to
confusion in both clinical practice and research, leading to recommendations for revision
in DSM-V to modify the postpartum onset specifier within the major depression
diagnosis to begin within six months following birth (Jones, 2010).
Working Definitions
Postpartum mood disturbances, as classified today, range from postpartum blues
to nonpsychotic major depression to depression with psychotic features. Postpartum
blues are a transient state of heightened emotional reactivity that affects between 50%
and 80% of new mothers (Miller, 2002; O’Hara & Segre, 2008). The blues are not
typically considered a disorder necessitating professional intervention. Women with
postpartum blues exhibit irritability, emotional lability, forgetfulness, confusion, and
anxiety. Postpartum blues are short-lived with acute onset typically occurring between
birth and two weeks postpartum and persisting from a few hours to a few days, with little
evidence of long-term negative consequences (O’Hara & Segre, 2008). The propensity to
develop postpartum blues is unrelated to psychiatric history, environmental stressors,
breastfeeding, or parity (Miller, 2002). However, those factors may influence whether
the blues lead to major depression.
Postpartum nonpsychotic depression constitutes a major depressive episode with
clinical symptoms that onsets within four weeks of giving birth. Symptoms of
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postpartum depression (PPD) may include irritability, anhedonia, sleep disturbance,
fatigue, and anxiety. Although DSM requires symptoms to appear by four weeks
postpartum, the literature has used this time frame loosely in defining PPD. While some
studies assert that the majority of cases have an onset within six weeks postpartum
(Stowe & Nemeroff, 1995), others report that symptoms of PPD may not appear until six
months after delivery (Beck, 1998; Gold, 2002; Miller, 2002; Spinelli, 1998). As a result,
most scientific literature has used more liberal criteria to diagnose PPD, and as a result of
these discrepancies, initial recommendations for revisions to DSM-V propose extending
the duration of the onset specifier to six months postpartum.
Finally, postpartum psychotic depression is the most severe and least common
disorder. It is reported to occur in only 1 or 2 of every 1000 women (Kendell, Chalmers,
& Platz, 1987). The psychosis, manifested by delusions, hallucinations, or both, typically
occurs in the first three weeks of birth (Munk-Olsen, Laursen, Pedersen, Mors, &
Mortensen, 2006). As compared with nonpostpartum mood episodes, there is more
disorientation and lability in postpartum episodes as well as abnormal or obsessive
thoughts. The symptoms constitute a psychiatric emergency and may warrant
hospitalization.
Prevalence of Postpartum Depression
The current body of scientific literature exhibits a wide variance in reports of the
prevalence of PPD. Rates of PPD have been reported to be between 7% and 15% in adult
women (Gavin et al., 2005; O’Hara & Swain, 1996; Vesga-Lopez et al., 2008). The
variance is due in part to the lack of clearly defined diagnostic criteria, including
conflicting definitions of the onset and duration of the postpartum period. As described
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above, DSM-IV requires the episode of major depression to begin within four weeks of
birth, while ICD-10 permits designation of a postpartum depressive disorder within six
weeks of delivery. In research, investigators’ definitions have varied and lengths of time
up to one year following birth have been used (Wisner, Perel, Peindl, & Hanusa, 2004).
Additionally, distinguishing between depressive symptoms and the normal
sequelae of childbirth including changes in weight, sleep, and energy, is a further
challenge complicating clinical diagnosis. Symptoms may be minimized by the
professional or the mother as normal. Furthermore, physical causes which may
contribute to depressive symptoms (including anemia, diabetes, and thyroid dysfunction)
have not been consistently excluded in research studies on prevalence rates of PPD.
Finally, the failure of mothers to report their symptoms has further confounded current
prevalence rates. It has been estimated that only 20% of women report their symptoms to
a professional (Gold, 2002) leaving many cases of PPD, up to 50%, unrecognized and
even more cases untreated (Murray & Cooper, 1997).
Consequences of Postpartum Depression
The consequences of untreated postpartum depression have been well
documented in the literature. PPD disrupts the relationship between the mother and the
infant, which can have short and long-term adverse effects. PPD also has a dramatic
impact on the mother’s ability to function, enjoy relationships, cope with the stresses, or
appreciate the joys of parenthood. Major depression creates suffering regardless of
timing; however, depression during the postpartum is exacerbated by substantial demands
on new mothers including infant care, household responsibilities, and often returning to
work after a brief maternity leave (O’Hara, 2009). The deleterious effects of PPD on
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offspring, the marital relationship, and on mothers are clinically significant and are
further outlined below.
Effects on Offspring
The adverse impact of maternal mental illness on offspring has been researched at
length (Forman et al., 2007; Goodman, 2007; Tronick & Reck, 2009; Weissman, Warner,
Wickramartne, Moreau, & Olfson, 1997). These investigations have indicated that
women suffering from PPD tend to be less responsive to their infants and report greater
difficulty with infant feeding, crying, and overall fussiness than non-depressed mothers
(Goodman & Brand, 2008). Similarly, studies have shown a positive correlation between
maternal PPD and greater difficulty learning effective infant care taking and parenting
skills (Fowles, 1996) as well as with interpreting infants’ affective communication
(Tronick & Reck, 2009). Furthermore, some studies have found a positive correlation
between mothers with PPD and incidence of child abuse and neglect (Nonacs & Cohen,
1998; Spinelli, 1998). These behaviors have a well documented, adverse effect, on
mother-infant attachment (Campbell, Cohn, & Meyers, 1995; Logsdon, Wisner, & PintoFoltz, 2006; Murray & Cooper, 1996, 1997; Teti, Gelfand, Messinger, & Isabella, 1995).
Several other studies have shown that depression may affect not only a mother’s
interaction with her infant, but also her perception of the infant. Depressed mothers have
been shown to perceive their infants more negatively and as more difficult to care for
than non-depressed controls view their infants (Fowles, 1996; Murray & Cooper, 1996).
Murray (1992) concluded that if normal maternal communication is experimentally
disrupted for even brief periods, infants as young as six weeks old respond with distress
and avoidance. A recent study found that early maternal negative perceptions of the
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infant predicted negative temperament and behavior problems eighteen months later
(Forman et al., 2007). Therefore, the mother’s negative perception of the infant in
combination with her inability to respond effectively may lead to longer-term
consequences for the child.
One of the earliest consequences of postnatal depression on infants is emotional
disturbance. Offspring of mothers suffering from PPD tend to demonstrate depressive
symptoms at an early age. Research indicates that infants of mothers with PPD exhibit
more negative facial expressions and vocalizations than infants of non-depressed mothers
(Beck, 1998; Cooper & Murray, 1997; Goodman & Brand, 2008; Murray & Cooper,
1996). For example, one study found that maternal PPD predicted a negative affective
response from their infants in response to a still-face interaction with their mother at six
months (Moore, Cohn, & Campbell, 2001). Furthermore, studies have found infants
exhibit depressive behavior not only with their mother, but also with non-depressed
adults (Fields et al., 1988). Finally, a meta-analysis examining the effects of PPD on
child development also found that exposure to PPD had a significant effect on children’s
emotional development (Beck, 1998).
In addition to the adverse effects on infants’ moods, research has also indicated
that exposure to maternal depression may lead to more insidious, longer-lasting
consequences. Most commonly, these consequences include emotional and behavioral
problems in early childhood (Cogill, Caplan, Alexandra, Robson, & Kumar, 1986;
Cutrona & Troutman, 1986; Goodman & Brand, 2008; Grace, Evindar, & Stewart, 2003;
Josefsson et al., 2001; Milgrom, Westley, & Gemmill, 2004; Murray & Cooper, 1996,
1997; Sharp et al., 1995; Whiffen & Gotlib, 1989). Studies have found a positive
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correlation between exposure to postnatal depression and externalizing behaviors in
preschoolers and elementary school aged children (Luoma et al., 2001; Murray, Sinclair,
Cooper, Ducournau, & Turner, 1999; Sinclair & Murray, 1998). Additionally, studies
have found that persistent exposure to PPD predicts low social competence and low
adaptive functioning (Luoma et al., 2001) as well as greater difficulty adjusting in the
context of school (Sinclair & Murray, 1998). These findings suggest that, while maternal
behavior varies with changing circumstances, exposure to postpartum depression may
have an enduring influence on child psychological adjustment.
In addition to emotional and behavioral disturbance, research has also
demonstrated cognitive delay in the children of postnatally depressed mothers on
cognitive tests. A significant positive correlation between exposure to PPD and infant
cognitive delay has been found at twelve months (Cooper & Murray, 1997) and eighteen
months (Murray & Cooper, 1996) as compared to infants of nondepressed mothers.
Similarly the same relationship between exposure to PPD and significant cognitive
deficits has been found in preschool and school aged children (Cogill et al., 1986). While
it is important to note that causal links cannot be inferred from these correlations, the
association between maternal postpartum depression and children’s lower cognitive
performance, points to ways in which PPD might exert its impact.
Effects on Marital Relationship
Evidence also suggests that PPD may have a harmful effect on the quality of the
marital relationship (Campbell, Cohn, Flanagan, Popper, & Meyers, 1992). Fishel (2004)
states that men sometimes withdraw, feel blamed, or neglected during this highly
charged, emotional time. Viinamaki, Niskanen, Pesonen, and Saarikoski (1997), found
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that partners of women experiencing PPD reported their relationships deteriorated during
pregnancy. These relationships had not improved when the same group was surveyed
again two years later. In addition to feelings of confusion and anger, partners are also at
risk for developing mood symptoms (Campbell et al., 1992; Paulson & Bazemore, 2010)
because of the significant emotional burden the family unit endures as a result of the
mother’s struggle with PPD.
Effects on Mothers
Postpartum depression has a dramatic impact on the mother’s ability to function,
enjoy relationships, cope with the stresses, and appreciate the joys of parenthood.
Women suffering from PPD may endure more serious sequelae if the syndrome goes
untreated. The depressive episode can become a precursor of recurrent depression and
the mother may be at risk for developing a chronic depressive disorder (Andrews-Fike,
1999; Nonacs & Cohen, 1998). In fact, Spinelli (1998) estimates women who have a
history of PPD to be 300 times more likely to have another episode of PPD in subsequent
pregnancies. Finally, if untreated, the mother may be at greater risk to engage in
unhealthy behaviors such as excessive consumption of alcohol and smoking cigarettes
(Ross & Dennis, 2009; Whitaker, Orzol, & Kahn, 2007).
In addition to psychological distress, the risk for suicidality is significantly
elevated among depressed women during the postpartum period, and suicide has been
found to be one of the leading causes of death in this depressed population (Appleby,
Mortensen, & Faragher, 1998). While suicide deaths and attempts are lower during the
postpartum than in the general population of women, when deaths do occur in the
postpartum, suicides account for up to 20% (Lindahl et al., 2005). When a woman with
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PPD becomes suicidal, she may also consider killing her infant and young children, not
usually out of anger but stemming from a desire not to abandon her children (Spinelli,
2004). Self-harm ideation is more common than attempts or deaths, with thoughts of
self-harm during the postpartum ranging from 5 to 14% (Lindahl et al., 2005). Therefore,
the clinical significance of PPD and its impact on mothers is compelling. Based on the
magnitude of the potential consequences of PPD, it is imperative researchers continue to
understand the disorder and its causes.
Causes of Postpartum Depression
One of the most commonly posited theories of the cause of postpartum depression
is hormone based. Many have theorized that the rapid decline in the levels of
reproductive hormones that occurs after delivery overwhelmingly contributes to the
development of depression in susceptible women. Furthermore, the biological changes
underlying postpartum blues may lead to clinical depression in the context of genetic
vulnerability, environmental stress, or insufficient social support. There is indirect
evidence to support the notion that hormonal imbalance causes PPD. In one study, which
simulated the postpartum state by administering hormones and rapidly withdrawing them,
it was significantly more likely to produce depression in women with a history of
postpartum depression than in women with no history of depression (Bloch et al., 2000).
Therefore, women with a history of postpartum depression may be differentially sensitive
to the effects on mood of hormone withdrawal. However, there is no direct evidence that
hormonal imbalance causes PPD and although it is tempting to attribute PPD to hormonal
decline, other psychosocial factors may predispose women to the condition. Thus, at this
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time there is no clear cause of postpartum depression and there are likely many
psychosocial contributory factors.
Predictors of Postpartum Depression
Beginning in the 1980’s, research on the predictors of postpartum depression was
initiated. The researchers found that a number of psychosocial and biological variables
were significantly correlated with postpartum depression. Several meta-analyses have
been conducted to determine the magnitude of the relationship between frequently cited
predictor variables and postpartum depression (Beck, 1996; Beck, 2001; O’Hara &
Swain, 1996; Robertson, Grace, Wallington, & Stewart, 2004). Based on the synthesis of
these results, psychosocial variables consistently linked to PPD include poor social
support, poor marital relationship, stressful life events, and low self-esteem. Perhaps the
strongest predictors of the development of PPD were biologically based. A history of
depression, including recurrent MDD or a past episode of PPD, independently predicted a
new onset of PPD. Additionally, the strongest predictor of PPD, according to several
studies, is depression during pregnancy (Beck 1996; O’Hara & Swain, 1996). While this
suggests that hormones may play a role in the development of PPD, psychosocial
variables also clearly impact the onset.
Social Factors
Several psychosocial variables have consistently been found to be related to PPD.
These include low social support, poor marital relationship, stressful life events, and
having low self-esteem. It is thought that increased support and self-esteem may serve as
buffers against the stresses associated with the postpartum phase. Each of these variables
is discussed in more detail below.
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Social support. Low social support has consistently been linked to the
development of PPD (Cutrona, 1984; O’Hara, 1986; Robertson et al., 2004). Each of the
major meta-analytic studies concluded that poor social support is a significant predictor
of PPD. Robertson and colleagues (2004) and O’Hara and Swain (1996) found moderate
effect sizes, d = -0.64 and d = -0.63, respectively, between social support and PPD.
Additionally, field observations have found that cultures with an apparently low
prevalence of PPD are characterized by strong social support for new mothers such as
help with child care, special foods, ritual baths, or return of the mother to her home of
origin (Miller, 2002).
Poor marital relationship. Marital conflict has also been linked to the onset of
PPD. Most commonly, marital dissatisfaction as measured by a lack of attachment to
one’s partner is positively correlated with PPD (Eberhard-Gran, Eskild, Tambs,
Samuelson, & Opjordsmoen, 2002; O’Hara, 1986; Robertson et al., 2004). Metaanalyses of the relationship between the two has demonstrated a moderate effect size
(Beck, 1996; Beck 2001; Robertson et al., 2004) at, r = 0.35, r = 0.38 to 0.39, and d=
0.39, respectively. While marital discord alone does not fully account for the
development of PPD, a supportive marital relationship may serve as a buffer against
depression that can result subsequent to birth.
Stressful life events. Life stress has consistently emerged as a significant
predictor of PPD (O’Hara et al., 1984; Paykel, Emms, Fletcher, & Rassaby, 1980;
Righetti-Veltema, Conne-Perreard, Bousquet, & Manzano, 1998). The major metaanalytic studies found moderate effect sizes with stress due to life events. Robertson and
colleagues (2004) and O’Hara and Swain (1996) reported a Cohen’s d of 0.61 and 0.60
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respectively. Similarly, Beck (1996, 2001) reported moderate effect sizes at r = 0.40 and
r = 0.36 to 0.41, respectively. Stressful life events during the year preceding childbirth
have been detected as important predictors, especially financial and professional
difficulties (O’Hara et al., 1984; Righetti-Veltema et al., 1998).
Self-esteem. Self-esteem has also emerged as a significant predictor of PPD. In
Beck’s (2001) meta-analysis of 84 studies examining PPD and its predictors, a moderate
relationship between PPD and self-esteem, r = 0.45 to 0.47, was found. It may be that
high self-esteem serves as a buffer between the negative effects of stressful life events
and the increased fragility of the ablest women during the postpartum period. Therefore,
mothers with high self-esteem may have greater ability to withstand stressors that may
contribute to the likelihood of developing postpartum depression.
Other factors. Several other variables have demonstrated inconclusive results in
the literature. For example, the literature concerning the impact of obstetrical
complications shows little agreement. While some have found that complications during
pregnancy and delivery are a predictor of PPD (Campbell et al., 1992), other studies have
found that the specialized care the woman receives may actually decrease the onset of
PPD (Paykel et al., 1980). Likewise, some investigators have found a strong association
between PPD and not breastfeeding (Eberhard-Grad et al., 2002; Misri, Sinclair, & Kuan,
1997); however, others have not found the same relationship (McCoy et al., 2008).
Socioeconomic status has also been inconsistently linked to PPD, with some researchers
reporting strong associations (Bernazzani, Saucier, David, & Borgeat, 1997; RighettiVeltema et al., 1998) and others finding small effect sizes (Beck, 2001; Robertson et al.,
2004). Additionally, inconclusive results have been reported with regard to unwanted
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pregnancy as it emerges as a significant predictor in some studies (Beck, 2001), but not in
others (O’Hara & Swain, 1996). Finally, other potential predictors for PPD cited as
inconclusive in the literature include fewer years of education (Davis, Edwards, Mohay,
& Wollin, 2003), a history of childhood sexual abuse (Buist & Barnett, 1995), and
childcare stress (Honey, Bennett, & Morgan, 2003).
Depression History
In addition to social factors, depressive history is also a strong predictor of PPD.
Research has indicated that baby blues, a history of MDD, a previous episode of PPD,
and depression during pregnancy each independently predict PPD. Additionally, several
researchers have identified depression during pregnancy to be the strongest predictor of
PPD (Beck, 1996; O’Hara & Swain, 1996; Robertson et al., 2004).
Postpartum baby blues. Baby blues is a well-established risk factor for PPD
(Bloch, Rotenberg, Koren, & Klein, 2005; Stowe & Nemeroff, 1995). While the blues do
not require intervention, it is important to note that this reportedly normal syndrome may
lead to later depression. Up to 20% of women with the blues will experience major
depression in the first postpartum year (Campbell et al., 1992; O’Hara, 1987).
History of major depressive disorder. History of major depressive disorder has
consistently been identified as a strong risk factor for PPD (Bloch et al., 2005; Stowe &
Nemeroff, 1995). In fact, a past episode of depression is commonly one of the strongest
predictors of PPD as women with a history of an affective disorder have a 1:3 chance of
developing PPD (Appleby et al., 1998). Similarly, a previous episode of PPD has been
found to put women at considerable risk for recurrent episodes following subsequent
pregnancies (O’Hara, 1991). In fact, Spinelli (1998) estimates women with a history of
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PPD to be 300 times more likely to have another episode of PPD in subsequent
pregnancies.
Depression during pregnancy. Depression during pregnancy has been found to
be a strong predictor of postpartum depression (Beck, 1996; Robertson et al., 2004;
Terry, Mayocchi, & Hynes, 1996; Verkick, Pop, Van Son, & Van Heck, 2003). In the
meta-analyses completed by Robertson and colleagues (2004), O’Hara and Swain (1996),
and Beck (1996) the strongest predictor of postpartum depression was depression during
pregnancy, d = 0.75, d = 0.75, and r = 0.51, respectively. Therefore, depression during
pregnancy has consistently emerged as a strong predictor of PPD.
Treatment of Depression During Pregnancy
It is not clear whether the treatment of major depression during pregnancy and the
early postpartum phase can protect women from the development of PPD. It is, however,
an important empirical question considering the strong predictive relationship between
depression during pregnancy and the onset of PPD. Treatment that both reduces maternal
depression and offers protective advantages postpartum is advantageous not only for the
woman herself, but also for the fetus, infant, and other family members. Empirical
research on treatment during pregnancy during the past decade has focused largely on
pharmacological, psychotherapeutic, and alternative therapies with few definitive results.
Therefore, treatment options for depressed pregnant women are frequently limited.
Pharmacological Treatment
With the advent of effective and well-tolerated pharmacological treatments for
major depression, a growing number of women have been treated with psychotropic
medication during their reproductive years. In 2003, approximately 13% of women took
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an antidepressant medication at some point during pregnancy, a rate that doubled since
1999 (Cooper, Willy, Pont, & Ray, 2007). The clinician faces certain challenges when
treating a depressed woman during pregnancy. All psychotropic medications diffuse
readily across the placenta and no psychotropic medication has been approved by the
U.S. Food and Drug Administration for use during pregnancy, nor have any
antidepressant drug efficacy trials been completed in depressed pregnant women
(Yonkers, Smith, Gotman, & Belanger, 2009). Although data has accumulated
suggesting that some medications may be used safely during pregnancy, current
knowledge regarding the risks of prenatal exposure to psychotropic medications is
incomplete. Clinical guidelines for the pharmacological treatment of depression during
pregnancy recommend carefully weighing the risks to the women and fetus associated
with no treatment relative to the risks of treatment (Yonkers et al., 2009).
Among antidepressant medications, selective serotonin reuptake inhibitors
(SSRIs) are the most widely used in the general population (Mann, 2005) as well as
among pregnant women (Reefhuis, Rasmussen, & Friedman, 2006). Fluoxetine, the first
SSRI to be marketed, was introduced in 1988 and soon became the most frequently
prescribed medication for depression worldwide (Morrison, Riggs, & Rurak, 2005).
Other currently prescribed SSRIs include sertraline, paroxetine, citalopram, escitalopram
and fluvoxamine.
Selective serotonin reuptake inhibitors (SSRIs). SSRIs are among the most
commonly used antidepressant medications, with a prescription frequency of 2.3% in
pregnant women (Reefhuis, Rasmussen, & Friedman, 2006). Potential adverse effects of
maternal SSRI treatment on the developing embryo or fetus can be categorized into five
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types: miscarriage; malformations; neonatal toxicity or withdrawal; prematurity or low
birth weight; and functional abnormalities, including long term neurocognitive effects
(Alwan & Friedman, 2009).
The current data on SSRI exposure does not support specific morphological
teratogenic risks. The majority of studies have focused on cardiac malformations and
have found no increased risk subsequent to in utero SSRI exposure (Alwan, Reefhuis,
Rasmussen, Olney, & Friedman, 2007; Louik, Lin, Werler, Hernandez-Diaz, & Mitchell,
2007; Malm, Klaukka, Neuvonen, 2005; Yonkers et al., 2009). There has been some
evidence that exposure to fluoxetine during the first trimester increased risk for minor
cardiac malformations (Kallan & Otterblad Olausson, 2007; Kallan & Otterblad
Olausson, 2006); however, other large projects have disputed these findings (Alwan et
al., 2007; Louik et al., 2007). There has also been evidence of increased risk for cardiac
malformations associated with the use of paroxetine in the first trimester. A 2007 metaanalysis found in utero exposure to paroxetine resulted in twice as many echocardiograms
in the first year of life (Bar-Oz et al., 2007) and other researchers found a significant
association between 1st trimester use of paroxetine and right ventricular outflow tract
obstruction defects (Louik et al., 2007). According to Alwan and Friedman (2009), first
trimester maternal paroxetine use may increase the risk for cardiac anomalies about 1.5fold, with a risk of approximately 1%. Although maternal SSRI treatment early in
pregnancy does not appear to increase the overall risk of birth defects greatly, SSRI
treatment during the first trimester of pregnancy has been associated with an increased
risk of cardiac defects. While overall risk of congenital malformation following early
prenatal exposure appears low, further data are needed to ensure clinical confidence.
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A number of studies have shown that maternal SSRI treatment late in pregnancy
can impair neonatal adaptation. Several studies have indicated that third trimester
exposure may increase risk for persistent pulmonary hypertension (PPHN), a rare but
serious condition which can result in neonatal hypoxia (Chambers et al., 2006; Kallen &
Olausson, 2008). Research has suggested a rate of absolute risk 3-6 per 1000 among
infants subsequent to third trimester exposure (Kallen & Olausson, 2008). Other research
findings indicate poor neonatal adaptation manifested by greater rates of respiratory
distress following exposure to paroxetine in the 3rd trimester (Costei, Kozer, Ho, Ito, &
Koren, 2002) or exposure to paroxetine, fluoxetine, or sertraline in the 2nd or 3rd trimester
(Oberlander, Fitzgerald, Kostaras, Rurak, & Riggs, 2004). Finally, one study found that
women who have endured longer periods of SSRI treatment, as opposed to shorter
periods of treatment, were at higher risk of delivering an infant with respiratory
complications (Oberlander, Warburton, Misri, Aghajanian, & Hertzman, 2008).
In addition to respiratory distress, a cluster of other symptoms associated with late
pregnancy SSRI exposure has been consistently reported during the immediate days
following birth. Reported findings among newborn infants whose mothers took an SSRI
in late pregnancy include temperature instability, hypoglycemia, tachypnea, irritability,
and seizures (Chambers, Johnson, Dick, Felix & Jones, 1996; Costei et al., 2002).
Additionally, analyses of the Swedish Medical Registry found that 649 SSRI exposed
infants (citalopram, paroxetine, fluoxetine or sertraline) as well as SNRI exposed infants
(venlafaxine) exhibited greater risk for neonatal adaptation compared to all other infants
in the database (Kallen, 2004). These risks included respiratory distress, hypoglycemia,
lower Apgar scores, and convulsions. Some difficulty with neonatal adaptation is
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apparent in about 30% of newborns whose mothers are treated with SSRIs late in
pregnancy, though symptoms in newborns are transient and tend to resolve within two
weeks following delivery (Chambers et al., 1996; Moses-Kolko et al., 2005; Oberlander
et al., 2004; Oberlander et al., 2008).
The rate of preterm birth (<37 weeks gestation) in the United States is 12.7% and
is a leading cause of perinatal mortality (Yonkers et al., 2009). There is substantial
evidence that preterm birth is higher among women taking antidepressant medication
during pregnancy (Chambers et al., 1996; Costei et al., 2002; Djulus et al., 2006; Kallen,
2004; Simon, Cunningham, & Davis, 2002). Additionally, mothers who use SSRIs late
in pregnancy have on average a three-fold increased risk of having a premature baby
(Alwan & Friedman, 2009). Further studies show that the effects of SSRIs on gestational
age are dependent on the duration of in utero exposure and longer exposure leads to
decreased gestational age (Oberlander et al., 2008).
Finally, there has been limited research examining the longer term effects of SSRI
exposure in utero. One study found that children born to women treated with SSRIs
during pregnancy were delayed in their psychomotor development and fine motor control
at six to forty months of age compared to children of untreated depressed mothers
(Casper et al., 2003). Additional research is needed to better understand potential long
term consequences of in utero exposure to SSRIs.
Given the current body of research demonstrating the fetal effects of maternal
SSRI treatment during pregnancy, providers are left with a dilemma. It is imperative that
the potential risks and benefits of discontinuing (or continuing) SSRI treatment during
pregnancy be assessed thoroughly and discussed with each patient. Guidelines for the
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treatment of depressed pregnant women have been published and are available to
providers (Yonkers et al., 2009).
Tricyclic antidepressants (TCAs). While an increasing number of women are
being treated with SSRIs during pregnancy, tricyclic antidepressants remain a common
alternative. They tend to be less frequently prescribed due to adverse side effects for the
mother, particularly constipation and orthostatic hypotension, which may be exacerbated
by pregnancy (Payne & Meltzer-Brody, 2009). Early case reports suggested a possible
association between 1st trimester exposure to TCAs and limb malformation; however,
more recent studies have failed to find a significant association between fetal exposure to
TCAs and risk for any major structural malformations (Altshuler et al., 1996; Cohen &
Altshuler, 1997; Simon et al., 2002). Research has found evidence for neonatal toxicity
in infants exposed to TCAs at or near the time of delivery. These have included TCA
withdrawal syndromes with characteristic symptoms of jitteriness, irritability and seizure
(Kallen, 2004) as well as increased preterm delivery, increased risk for respiratory
distress syndrome, endocrine and metabolic disturbances, and temperature regulation
disorders (Davis et al., 2007). Finally, with regard to longer term neurobehavioral
effects, further investigation is needed.
Psychotherapeutic Treatment
Due to maternal treatment preferences and concerns about fetal and infant health
outcomes associated with antidepressant treatment, non-pharmacological treatment
options are needed. A systemic review reported that patients with MDD in primary care
prefer psychotherapy over antidepressant medication for treatment if psychotherapy is
available (van Schaik et al., 2004). In addition, mothers remain hesitant to take
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medication without definitive studies regarding long-term effects on child development
(Sit & Wisner, 2005). Given these preferences, and the incomplete knowledge regarding
the risks of prenatal exposure to psychotropic medications, the need for controlled
psychotherapeutic treatment trials is great.
Despite the need for controlled clinical trials, research in this area is limited. The
only form of psychotherapy that has been specifically tested during pregnancy and found
to be effective for pregnant women is interpersonal therapy (IPT) (Grote et al., 2009;
Spinelli & Endicott, 2003). IPT is a well established treatment for depression in the
general population (Klerman, Weissman, Rounsaville, & Chevron, 1984). It became
attractive as a treatment for perinatal depression because of its focus on disrupted
interpersonal relationships, disputes, and making role transitions. Because of the unique
and developmental problems associated with gestation, IPT trials with pregnant women
also include an additional focus on pregnancy complications in which problems specific
to pregnancy are addressed (undesired pregnancy, complications, multiple births, and
congenital anomalies) (Grote et al., 2009; Spinelli & Endicott, 2003).
The initial results of studies using IPT to treat depressed pregnant women are
promising. To date, there have been few randomized controlled clinical trials of
interpersonal therapy with depressed pregnant women (Grote et al., 2009; Spinelli &
Endicott, 2003). Spinelli and Endicott (2003) found a significant improvement in
depression scores among women assigned to 16 weeks of interpersonal psychotherapy as
compared to a parenting education control program on all measures of mood at
termination (Edinburgh Postnatal Depression Scale, the Beck Depression Inventory, and
the Hamilton Depression Rating Scale) and recovery criteria were met in 60% of the
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women treated with interpersonal psychotherapy. Grote et al. (2009) found a significant
reduction in depression diagnoses (using SCID criteria) among participants assigned to
IPT compared to those in enhanced usual care following an eight week treatment during
pregnancy which was maintained at six months postpartum. Additional uncontrolled
trials of IPT during pregnancy have demonstrated significant improvement in depressive
symptoms following treatment in pregnancy (Grote et al., 2004; Swartz, 2004). Further
research is necessary to support the efficacy of other forms of psychotherapy for
depression during pregnancy.
While psychotherapy is a safe treatment option during pregnancy, it is not readily
available in the HMO dominant market and may not be acceptable to all pregnant
women. Moreover, while initial evidence suggests that depressed pregnant women may
benefit from interpersonal therapy during pregnancy, additional research is needed to
further support this finding and identify other efficacious psychotherapies. Thus the
current treatment options for depressed pregnant women are quite limited and studies of
novel, safe and accessible treatments are needed for depression during pregnancy.
Complementary and Alternative Medicine (CAM)
In addition to depressed pregnant women, non-pregnant depressed individuals are
also dissatisfied with current treatment options. Surveys of the United States population
report that 22.4% of patients meeting criteria for major depressive disorder used
alternative treatments in the past 12 months (Unutzer et al., 2000), either alone or in
conjunction with traditional treatments, and women were more likely than men to use
alternative treatments (Mackenzie, Taylor, Bloom, Hufford, & Johnson, 2003; Tindle,
Davis, Phillips, & Eisenberg, 2005). The popularity of alternative treatments for
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depression may, in part, suggest that conventional treatments fail to provide full or lasting
remission. For example, the NIMH Collaborative Study of the Psychobiology of
Depression, a prospective, naturalistic, longitudinal investigation on the course of illness
in MDD, identified the cumulative probability of recurrence at nearly 30% after six
months follow-up, almost 40% after 12 months of follow-up (Keller, Lavori, Lewis, &
Klerman, 1983), and the risk of recurrence increased by 16% with each successive
recurrence (Solomon et al., 2000). The high rate of recurrence among those suffering
from MDD may be attributed to a number of factors, but certainly suggests a need for
additional, efficacious and accessible treatments.
While there is a paucity of research in this area, complementary and alternative
medicine (CAM) interventions have generated recent interest. Many of these
interventions are desirable because they can easily be added to a conventional treatment
plan with little risk and general health benefits for the patient. Research in this area has
focused on supplements including St. John’s Wort, S-Adensoyl-Methionine (SAMe),
folate, 5-Hydroxytryptophan (5-HTP), and omega 3 fatty acids as well as bright light
therapy, massage and exercise. Among CAM treatments, one of the more compelling
areas of research has been on the use of acupuncture as a treatment for depression,
including depression among pregnant women.
Acupuncture. Among CAM treatments, acupuncture has become a subject of
great interest and one of the most researched complementary therapies. Acupuncture, as
practiced in the United States, is used within the framework of traditional Chinese
medicine, in which organ systems are thought to be connected via energetic channels and
disease states are thought to arise from imbalance within those channels. Within the
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context of Chinese medicine, the focus is not on the diagnosis and treatment of disease
but rather on the detection of energetic imbalances. Because the patient is considered as
a totality of body and mind, both physiological and psychiatric symptoms are equally
important in the evaluation of patients and the resulting treatment prescribed.
Theory behind the use of acupuncture for depression. Chinese medicine
views health as a balance between the Yin and Yang forces, which are dependent upon
the proper circulation of vital energy, or Qi (chee), along the energetic pathways. Yin,
which is nourishing, grants the qualities of rest, tranquility, and quiescence. When Yin is
deficient, patients lack the qualities of receptivity and contemplation leading to agitation,
nerves, and uneasiness (Kaptchuk, 1983). Yang, which by contrast is activating, causes
transformation and change, providing the capacity to engage in life, react, and respond.
When Yang is deficient, patients are often paralyzed in fear, confusion, indecision, and
hopelessness (Kaptchuk, 1983). The balance of Yin and Yang depends on the capacity to
adapt and change and is related to health and disease. When Yin and Yang are in
balance, it allows for the natural flow of Qi which in turn optimizes health.
The proper circulation of Qi along energetic pathways, or meridians, sustains the
homeostasis of an individual (the balance of Yin and Yang). The experience of a
disorder, the nature of its symptoms, and the protocol for its treatment are determined by
the specific tendencies in every person toward a deficiency or excess of Yin or Yang
(Beinfield & Korngold, 1991). These tendencies precipitate personal patterns of reaction.
For example, in depressed individuals, patients may present with symptoms such as
lethargy, weakness, lack of motivation, and loss of appetite. Chinese medicine would
conceptualize these patients as manifesting a pattern of symptoms in which Yin is
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predominant and Yang is deficient. However, in patients presenting with anxiety,
irritability, agitation, increased appetite, and insomnia, Yang is predominant and Yin is
deficient. In many cases of depression, imbalances between Yin and Yang are often
linked to the liver network, the kidney network, and the heart network. The acupuncture
points utilized will therefore consist of points activating the meridians linked to each of
these organ systems depending on the symptom profile presented. Through activation
and subsequent circulation of Qi along these meridians in one’s body, homeostasis can be
reestablished and health optimized (Beinfield & Korngold, 1991).
In addition to releasing Qi stagnation in patients with depression, Chinese
medicine also links Shen, or the organizing force of the self, to emotional imbalance.
Shen organizes the emotional, mental and expressive life of the individual and is housed
by the heart organ network (Beinfield & Korngold, 1991). Therefore, an individual’s
response to the environment is determined by the health of the Shen. Inability to express
joy and fulfillment, confusion, and agitation that are experienced during a depressive
episode are conceptualized in Chinese medicine as manifestations of the heart’s lost
ability to enfold the Shen.
In summary, within the context of Chinese medicine, depression can be
understood as a complex energetic reaction pattern that involves a predisposing tendency
towards excess or deficiency of Yin or Yang, combined with varying degrees of Qi
stagnation and Shen disturbance. Chinese medicine provides a framework for
understanding symptom patterns from which an individually tailored acupuncture
treatment plan can be developed. Thus, acupuncture treatments for depression focus on

28
the symptom profile presented, which may include both physiological and psychiatric
symptoms.
Research on acupuncture treatment and depression. As a result of the need
for safe, effective, and affordable alternative treatments for depression, researchers began
to design and conduct randomized controlled trials to assess the efficacy of acupuncture
as a treatment for depression. Although several randomized clinical trials have reported a
significant reduction of depressive symptoms following treatment with acupuncture
(Allen, Schnyer, & Hitt, 1998; Eich, Angelink, Lehmann, Lemmer, & Kleiser, 2000; Luo
et al., 2003; Quah-Smith, Tang & Russell, 2005), generally the results appear
contradictory. For example, the first randomized controlled trial, which recruited a small
sample of woman with major depression, reported that after eight weeks of treatment
there was a significant difference in symptom reduction between acupuncture and
placebo groups on HRSD depression scores (Allen et al., 1998). However, in a larger
scale clinical trial published in 2006, including both men and women, the same authors
failed to support the efficacy of acupuncture as a monotherapy for major depression as
greater decreases in depressive severity were exhibited by both groups (acupuncture and
sham acupuncture) and the two groups did not differ from each other (Allen et al., 2006).
Because of the conflicting results achieved in different trials, several systemic
reviews have been completed. A 2007 systematic review, which compared acupuncture
with control conditions within nine randomized controlled trials, suggested some
evidence for the utility of acupuncture in depression. Acupuncture modalities were as
effective as antidepressants (Leo & Ligot, 2007). Additionally, a meta-analysis of eight
randomized, controlled trials supported acupuncture as an effective treatment that could
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significantly reduce the severity of depression (Wang et al., 2008). In a more recent
systemic review, containing data from 30 studies, overall there was insufficient evidence
of a consistent beneficial effect from acupuncture compared to controls or sham
acupuncture (Smith, Hay, & Macpherson, 2010). However, among the studies included,
two trials found acupuncture had an additive benefit when combined with medication
compared to medication alone and a subgroup of participants experienced a reduction in
depression with acupuncture alone compared to SSRIs. Generally, these conflicting
results are complicated by the variability across studies with regard to differences in
methodology, degree of experimental control, type of depression treated, and the outcome
measures used.
While the majority of research has examined the efficacy of treating depressed
men and women, a subset of research is developing that focuses specifically on the
treatment of women. As mentioned above, the first randomized, double-blind, placebocontrolled study on the efficacy of acupuncture for depression consisted of a sample of 38
women ages 18-45. In the study, Allen, Schnyer, and Hitt (1998) found acupuncture
provided significant depressive symptom relief; however, in a follow-up study (Allen et
al., 2006) in which men were also included in the sample, the results were not significant.
This may suggest that women of a childbearing age respond differently to the treatment
and perhaps the use of acupuncture is more beneficial to them. Based on the initial
findings of Allen and colleagues (1998), additional research has focused specifically on
the treatment of depressed pregnant women with the use of acupuncture.
Research focused on the use of acupuncture to treat depressed pregnant women
appears promising. In a prospective, controlled study of 51 mild to moderately depressed
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pregnant women, researchers reported depressive symptoms decreased by 60% in women
receiving acupuncture compared to 26% in the control group (Silva, 2007). In a
randomized, double-blind, placebo-controlled pilot study on the efficacy of treating major
depression during pregnancy with acupuncture, a significantly larger proportion of
participants responded to an acupuncture treatment specific for depression (68.8%
response rate) than to massage (31.6%); however, a statistically significant difference
was not found between acupuncture treatment specific for depression and the control
acupuncture group (47.4% response rate) (Manber, Schnyer, Allen, Rush & Blasey,
2004). These rates demonstrated comparable response rates to clinical trials of standard
treatments for depression, typically 50-70% (Elkin et al., 1989). Furthermore, in Manber
and colleagues (2004) pilot study, they found a significant main effect for response status
to the acute phase of treatment on depression symptom severity at ten weeks postpartum,
suggesting successful treatment with acupuncture or massage may result in an enduring
effect into the postpartum phase.
Based on these preliminary results, Manber et al. (2010) completed a randomized
controlled trial to examine the efficacy of acupuncture for treatment of depression during
pregnancy. Women who received eight weeks of acupuncture specific for depression
experienced a greater rate of decrease in depressive symptom severity compared to the
combined control groups (control acupuncture and massage) and compared to control
acupuncture alone. The women in the acupuncture specific for depression group also had
a significantly greater response rate (63%) compared to the combined controls (44.3%).
These results are meaningful when considering the length of treatment (eight weeks) is
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shorter than the duration of most psychotherapy trials (12-16 weeks), yet the response
rate remains comparable to those same trials.
Based on these findings, the use of acupuncture to treat depressed pregnant
women appears promising. Because of the lack of psychotherapies examined for efficacy
in pregnancy, along with concerns related to the use of antidepressants taken during
pregnancy, alternative treatments are needed for depressed pregnant women. The current
popularity and emergence of alternative treatments further suggests women are
dissatisfied with conventional treatments for depression during pregnancy. Based on
these concerns, it is imperative that researchers continue to pursue early detection of
depressive symptoms and prompt initiation of treatment during pregnancy, including
promising alternative treatments, in order to reduce the adverse consequences associated
with PPD.
Treatment During Pregnancy to Prevent Postpartum Depression
To date, the majority of studies completed examining treatment interventions for
postpartum depression have been implemented during the postpartum phase. Among
these, medication, alone or with CBT (Appleby, Warner, Whitton & Faragher, 1997;
Appleby et al., 1997; Suri, Burt, Altshuler, Zuckerbrow-Miller, & Fair, 2001),
interpersonal therapy (O’Hara, Stuart, Gorman, & Wenzel, 2000), and CBT (Chabrol et
al., 2002; Murray, Cooper, Wilson, & Romaniuk, 2003) produce the largest effect sizes
(Bledsoe & Grote, 2006). Few studies have examined whether treatment during
pregnancy can have an enduring effect into the postpartum. Although prevention
approaches hold much promise to improve the outcomes of both mother and offspring,
the field is in its developing stages. There have been few studies of prevention of
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depression in pregnant women and there are even fewer randomized control trials
focusing on depression during pregnancy through the postpartum period (Boyd, Pearson,
& Blehar, 2002). Despite this, postpartum depression provides an ideal opportunity for
prevention because its onset is preceded by a clear marker (giving birth), the period of
risk for illness onset is well defined, and a high-risk sample of mothers can be identified.
Additionally, pregnant women may be unusually open to making changes to improve
their mental health before their baby is born (Cowan & Cowan, 2000).
Empirical research targeting high-risk women during pregnancy, in attempt to
prevent postpartum depression, has been conducted largely in the last decade. The
categorization of high-risk women has varied across studies, but commonly requires
women meet one of the following: a personal history of depression, family history of
psychiatric disturbance, depressive symptoms during pregnancy, marital conflict, or
current negative life events. Interventions begin during pregnancy, often extend into the
early postpartum phase, and are largely psychotherapeutic.
Among interventions, initial support for the use of interpersonal therapy as a
preventative measure in asymptomatic high-risk women has been documented. Gorman
(1997) randomly assigned 45 high-risk women to receive preventive IPT or a no
treatment control. The intervention consisted of two individual sessions during
pregnancy (from 32 weeks to delivery) and three weekly sessions between two to four
weeks postpartum. At one month postpartum women in the intervention group were
significantly less likely to have experienced major depression compared to women in the
no treatment group (0% vs. 25%); however, at six months postpartum the difference
between groups was no longer significant (Gorman, 1997). Similarly, Zlotnick, Johnson,
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Miller, Pearlstein, & Howard (2001) randomized 37 low-income, high-risk women to
four weekly sessions of group interpersonally-oriented psychoeducation or to a control.
At three months postpartum women in the intervention group were significantly less
likely to have developed PPD (0%), compared to the control (33%) (Zlotnick et al.,
2001). These initial studies using a modified version of interpersonal therapy for
prevention provide promising results.
In addition to interpersonally-oriented interventions, group psychoeducation has
also been researched as a means to prevent PPD. While the format and content of the
groups varies greatly by study, the general focus tends to be on problem solving
strategies to avoid PPD as well as the importance of social support networks. Within this
line of research, the results are inconclusive. Brugha et al. (2000) conducted a
randomized prevention trial with 190 asymptomatic high-risk pregnant women consisting
of six 2-hour session groups during pregnancy and an additional session at eight weeks
postpartum. The intervention had no effect with respect to depressive symptomatology
or diagnostic status at three months postpartum (Brugha et al., 2000). Additionally,
Elliott Leverton, Sanjack, and Turner (2000) conducted an intervention with 99
asymptomatic high-risk pregnant women consisting of five group sessions during
pregnancy (beginning at 24 weeks) and six group sessions postpartum. The results
indicated significant differences with respect to level of depressive symptomatology at
three months postpartum, only for first time mothers, and no differences were found at 12
months postpartum (Elliott et al., 2000).
Finally, there has been some research suggesting that the presence of
antidepressants during a high-risk period may prevent the onset of another depressive
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episode. Wisner and colleagues (Wisner et al., 2001; Wisner et al., 2004; Wisner et al.,
2006), have studied the effects of starting treatment immediately after delivery compared
to watchful waiting in samples of asymptomatic high-risk mothers with a history of PPD.
In their initial study (Wisner et al., 2001), they compared nortriptyline to placebo and
found no significant differences between groups with regard to depressive
symptomatology. However, in their second study (Wisner et al., 2004), a 17 week trial of
sertraline (compared to placebo) resulted in significantly fewer recurrences of major
depression in those taking sertraline (7%) compared to placebo (50%). In addition, the
time to recurrence was also significantly longer in the sertraline treated women than in
the placebo treated women. Finally, in a more recent, definitive study, (Wisner et al.,
2006), the researchers found no differences between nortriptlyline and sertraline in an
eight week comparative trial with a 16 week continuation phase. The proportion of
women who responded and remitted did not differ, nor did the times to response and
remission.
Both psychosocial and pharmacologic treatment trials designed to prevent
postpartum depression in asymptomatic high-risk pregnant women have demonstrated
mixed results. The interpersonally-based interventions have fared better than more
general, educational based groups. The administration of an antidepressant for
prevention of postpartum depression in high-risk, asymptomatic women remains
inconclusive. The differences in outcome across studies may be due to variability on a
number of dimensions. These include: the qualification of high-risk, the type of
professional conducting the intervention, the type of intervention provided, as well as the
number of sessions and timing of the intervention. Researchers have recommended
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prevention interventions are conceptualized such that high-risk pregnant women continue
to be targeted (Stuart, O’Hara, & Gorman, 2003). This conceptualization suggests that
while interventions aimed at preventing acute PPD have not yet demonstrated strong
support, it is clinically compelling to promote advances for women at risk during
pregnancy.
While researchers have recommended that prevention interventions of postpartum
depression target asymptomatic high-risk pregnant women (Stuart et al., 2003), others
have taken this rational further by recommending that treatments be directly targeted at
depressed pregnant women (Austin, 2003). It is hypothesized that treating one of the
strongest predictors of postpartum depression, namely depression during pregnancy, may
reduce the likelihood of developing postpartum depressive symptomatology. In fact,
recent studies have suggested that the prevalence of depressive symptoms during
pregnancy is similar to that seen postpartum (Evans, Heron, Francomb, Oke, & Golding,
2001; Fergusson, Horwood, & Thorpe, 1996) and one study found that up to 40% of
postpartum depression began prenatally (Green & Murray, 1994). According to Austin
(2003), these figures suggest that evaluating ‘indicated’ interventions (i.e. in women with
existing symptoms or early diagnosis of depression in pregnancy) will likely be a more
fruitful approach than simply targeting high-risk women without current symptoms.
Furthermore, while the onset of depressive symptoms may occur after delivery,
there are a significant proportion of women who experience symptoms during pregnancy
that carry over into the postpartum period. Research indicates that the incidence and
severity of depression increases from the first to the third trimesters of pregnancy (Gotlib,
Whiffen, & Wallace, 1991) and several studies have found higher depressive scores
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during the last two months of pregnancy compared to the first eight weeks postpartum
(Evans et al., 2001; Hayes, Muller, & Bradley, 2001; Josefsson et al., 2001). Therefore,
when women develop symptoms during the latter part of pregnancy, prevention becomes
more difficult if treatment is implemented after delivery and an earlier intervention
becomes increasingly important.
In order to alleviate depression during pregnancy and prevent depressive relapse
postpartum, efficacious interventions are needed for high-risk, depressed pregnant
women. Moreover, because many women wish to avoid the risks associated with taking
antidepressants, the need for alternative interventions is great. While it is not clear
whether the treatment of a major depressive episode during pregnancy and the early
postpartum phase can protect women from the development of PPD, there is some
evidence to support this theory.
To date, there have been few studies to test this theory directly. Most notably,
Grote and colleagues (2004; 2009) have completed two studies examining the treatment
of depressed pregnant women using brief interpersonal therapy to prevent postpartum
depression. In 2004, they completed a pilot study with twelve women who received eight
sessions of brief IPT during pregnancy, followed by monthly maintenance IPT sessions
up to six months postpartum. The results indicated significant improvement on
depression symptom severity measures (EPDS, BDI, and HRSD) both at post-treatment
as well as at the six month postpartum assessment. Furthermore, in their 2009 study, 53
pregnant women received eight sessions of brief IPT during pregnancy, followed by
monthly maintenance IPT sessions up to six months postpartum. Similar to their pilot
study, the results indicated significant reductions in depression diagnoses and depressive
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symptoms before childbirth (three months post-baseline) and at six months postpartum.
These studies provide initial support for the notion that treating depressed pregnant
women may help to avert a postpartum depressive relapse.
While Grote and colleagues (2004; 2009) examined whether treatment during
pregnancy can reduce the likelihood of postpartum depression, more commonly studies
focusing on the treatment of depressed pregnant women have not instituted a postpartum
follow-up. As a result, there is very limited data in this area. In Manber and colleagues
(2004) pilot study examining the use of acupuncture treatment for depressed pregnant
women, the authors found a significant main effect for response status to the acute phase
of treatment on depression symptom severity at ten weeks postpartum. Few studies,
however, have offered exploratory information regarding postpartum follow-up
subsequent to treatment if assessed. For example, in Spinelli & Endicott’s (2003)
controlled trial of IPT compared to a parenting education program for depressed pregnant
women, they reported that seven of eight women treated with IPT had no postpartum
depression. In their control group, they found two of three available subjects had
postpartum depression, and one did not. Few inferences can be made from these data;
however, it emphasizes the importance of postpartum follow-up and the potential for
prevention.
Present Study and Hypotheses
Given the deleterious costs of postpartum depression to individuals and society,
prevention and treatment are large concerns. In the past decade, research has begun to
examine viable treatment options during pregnancy in order to prevent depressive
symptomatology in the postpartum phase. This research has largely included
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interventions targeting high-risk, asymptomatic, pregnant women. More recently,
recommendations have been made to direct these treatments at depressed pregnant
women because of the large number of cases of PPD which are carried over from
pregnancy, and also because depression during pregnancy is the strongest predictor of
PPD. Therefore, it has been hypothesized that treating depressed pregnant women will
be a more fruitful approach than simply targeting high-risk women without current
symptoms.
In addition to intervention timing, researchers have begun to expand viable
treatment options for pregnant and postpartum women. Studies of novel, safe, and
accessible treatments are greatly needed. Many mothers remain hesitant to take
medication both during pregnancy and in the postpartum phase without definitive studies
regarding long-term effects on child development (Sit & Wisner, 2005). Given these
preferences, and the incomplete knowledge regarding the risks of exposure to
psychotropic medications, the need for controlled alternative treatment trials is great.
The present study was designed to extend this recent body of work by examining
the role of treating depressed pregnant women with acupuncture and massage as a means
to manage mood symptoms and reduce the likelihood of postpartum depression. It was
conducted as part of a larger study which examined the efficacy of acupuncture for the
treatment of depression in pregnant women and included three treatment group
assignments: acupuncture needling points specific to depression, acupuncture needling
non-specific points, and massage. Therefore, the current study did not examine treatment
effects following the acute phase of treatment, but focused solely on the postpartum
period. More specifically, the study examined whether or not successful treatment of
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depression during pregnancy provided protection against the development of postpartum
depression and explored factors that predicted postpartum depression in this high-risk
group.
Rationale and Hypothesis One: Treatment Response and Postpartum Depression
Among interventions targeting asymptomatic high-risk women during pregnancy
to prevent postpartum depression, studies have demonstrated initial support.
Interventions using interpersonal therapy during pregnancy found participants were
significantly less likely to develop postpartum depression, compared to those who did not
receive treatment, at one month postpartum (Gorman, 1997) and three months postpartum
(Zlotnick et al., 2001). Additionally, among IPT studies targeting women already
experiencing depression during pregnancy, results have found participants maintain the
treatment effect up to six months postpartum (Grote et al., 2004; Grote et al., 2009). The
results of these studies, targeting both asymptomatic high-risk women and women
already experiencing depression during pregnancy, suggest that interventions focused on
high-risk women may result in an enduring effect in the postpartum phase.
Furthermore, in Manber and colleagues (2004) pilot study of treating 61
depressed pregnant women with acupuncture, they found a significant main effect for
response status to the acute phase of treatment on depression symptom severity at ten
weeks postpartum. These results revealed that, regardless of treatment modality, early
successful treatment of depression during pregnancy incurred protection against
postpartum depression in a high-risk group. A similar effect is expected in the current
study. Therefore, it is hypothesized that responders to the acute phase of treatment
during pregnancy, across all three treatment groups, will have better clinical outcomes at
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ten weeks, six months, and nine months postpartum than those who have not responded
to the acute phase of treatment. More specifically, the following hypotheses are proposed
with regard to clinical status in the postpartum phase:
Hypothesis 1(a): It is hypothesized that responders to the acute phase of
treatment during pregnancy, across all three treatment groups, will have better clinical
outcomes as measured by the Hamilton Rating Scale for Depression (the study’s main
outcome measure) compared to non-responders at ten weeks, six months, and nine
months postpartum.
Hypothesis 1(b): It is hypothesized that responders to the acute phase of treatment
during pregnancy, across all three treatment groups, will have lower depression symptom
severity scores as measured by the BDI-II compared to non-responders at ten weeks, six
months, and nine months postpartum.
Rationale and Hypothesis Two: Treatment and Relapse Rate
While it is hypothesized that responders will endure longer-term benefits from
their treatment, some women might experience re-occurrence of MDD during the
postpartum phase. The re-occurrence might represent a relapse into the index episode or
a recurrence into a new episode, depending on the time in remission. Women with a
history of depression, and particularly postpartum depression, are at increased risk for
relapse. Cohen et al. (2006) recently reported a five times higher rate estimate of relapse
among pregnant women who discontinued antidepressants compared to women who did
not discontinue antidepressants. Additionally, 26% of women who continued
antidepressants throughout pregnancy relapsed. The women in their study were
considered high-risk based on multiple episodes of MDD and early onset of illness;
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therefore, the results of the study cannot be extrapolated to the general population.
However, the cumulative probability of relapse among patients with MDD in the general
population after six months follow-up is nearly 30% and almost 40% after twelve months
of follow-up (Keller, Lavori, Lewis, & Klerman, 1983). Based on these estimates, it is
expected that a subset of women may experience re-occurrence of MDD during the
postpartum phase. Despite this, it is expected that the acupuncture group specifically
tailored to address depression related patterns of disharmony (SPEC) will fare better in
terms of time to relapse. More specifically, the following hypothesis is proposed:
Hypothesis 2: It is hypothesized that time to relapse will be sooner for
participants in the two control groups (acupuncture addressing nonspecific depression
pressure points (NSPEC) and prenatal massage (MSSG)) than for participants in the
SPEC group when examined at ten weeks, six months, and nine months postpartum.
Rationale and Hypothesis Three: Predictors of Postpartum Depression.
Historically, research on PPD has focused largely on its predictors. Among those
studies, a history of depression consistently emerges as one of the strongest predictors of
PPD. This includes a history of recurrent depression and a history of perinatal and
postpartum depression. Verkerk and colleagues (2003) reported a personal history of
depression and high depressive symptomatology during mid-pregnancy were the two
largest risk factors which predicted PPD. Depression during pregnancy, which is often
cited as the strongest predictor of PPD, is the most important inclusion criteria for women
to participate in the current study. It is expected that additional depressive history, will
lead to increased levels of depressive symptomatology in the postpartum period.
Additionally, women who have suffered from one episode of PPD experience increased
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risk for recurrence in the year following another birth (Wisner et al., 2004). Therefore, it
is hypothesized that clinical status during the postpartum will be worse for women with a
history of previous depressive episodes. More specifically, the following hypotheses are
proposed:
Hypothesis 3(a): It is hypothesized that women with a history of previous
episodes of depression will be more likely to meet criteria for MDD at any time point
during the postpartum (ten weeks, six months, or nine months postpartum).
Hypothesis 3(b): It is hypothesized that women with greater numbers of past
episodes of depression during pregnancy and postpartum will have higher depression
symptom severity scores as measured by the Hamilton Rating Depression Scale at six
months and nine months postpartum.
Exploratory Analyses: ROC Curve Approach
While a history of previous depressive episodes has consistently emerged as a
strong predictor of PPD, a second factor that appears to be associated consistently with
PPD is support. Several studies have found that women who were depressed postpartum
reported greater marital tension and more persistent feelings of being unloved by their
husbands (Eberhard-Gran et al., 2002; Gotlib et al., 1991; O’Hara, 1986; Whiffen, 1988).
These studies suggest that a lack of spousal support may play an important role in the
development of PPD.
Other factors related to the onset of PPD have not demonstrated consistent, strong
associations as compared to the evidence for history of depression and lack of support.
For example, some investigators have found a strong association between PPD and not
breastfeeding (Eberhard-Grad et al., 2002; Misri et al., 1997); however, others have not
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found the same relationship (McCoy et al., 2008). Socioeconomic status has also been
inconsistently linked to PPD with some researchers reporting strong associations
(Bernazzani et al., 1997; Righetti-Veltema et al., 1998) and others finding small effect
sizes (Beck, 2001). Additionally, inconclusive results have been reported with regard to
unwanted pregnancy (Beck, 2001; O’Hara & Swain, 1996), childhood sexual abuse
(Buist & Barnett, 1995), childcare stress (Honey et al., 2003), and obstetrical
complications (Campbell et al., 1992).
Because of the importance of understanding how factors beyond treatment
influence the development of PPD, exploratory analyses examine potential predictors of
PPD. While it is clear in the literature that both history of depression and spousal support
are strong predictors of PPD, other variables have not demonstrated conclusive results.
Thus, there was not a compelling rationale upon which to build a hypothesis for these
predictors of PPD. As a result, exploratory analyses were completed to ascertain the
extent to which these variables impact clinical status in the postpartum phase.

CHAPTER THREE
METHOD
Participants
Recruitment and Selection
Data for the present study was obtained from a research project funded by the
Agency for Healthcare Research and Quality, at the U.S. Department of Health and
Human Services, designed to examine the efficacy of acupuncture in the treatment of
depression during pregnancy. Data were collected at Stanford University, where the
Institutional Review Board approved the protocol. Written informed consent was
obtained from all participants at the time of enrollment.
Participants consisted of pregnant women with a current Major Depressive
Episode and were recruited between 2003-2007 in the San Francisco Bay Area
community. They were recruited from obstetric clinics and from advertisements in local
parent and baby magazines. Efforts were made to ensure adequate minority
representation in the study. These included initiating contacts in hospitals and clinics
with high attendance by minorities, placing brochures in libraries with higher minority
populations, and advertising in publications geared toward minorities.
Participants met the following criteria for inclusion: (a) ambulatory women (age ≥
18) with viable pregnancy, and between 12-30 weeks of gestation; (b) satisfy DSM-IV
criteria for a current Major Depressive Episode; and (c) obtain a minimum score of 14 on
44
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the 17-item Hamilton Rating Scale for Depression. Participants were excluded from
participation for the following reasons: (a) meeting criteria for a primary Axis I disorder
in the past two months, other than unipolar depression or social phobia; (b) Seasonal
Affective Disorder or current episode duration of two years or more (chronic depression);
(c) abnormal results on a laboratory screen including a thyroid panel and drug screen; (d)
serious uncontrolled medical conditions or conditions that may have a medical basis for
depression; (e) cluster B personality disorders; (f) confounding treatments for depression,
including any psychotherapy, herbs, or pharmacotherapy; (g) current use of any
prescribed psychotropic medication or any medication that impacts mood; (h) treatment
with ECT or vagal nerve stimulation in the past year; (i) current active suicidal potential
necessitating immediate treatment; (j) absence of prenatal care from an OB-GYN
practitioner in the community; and (k) any condition necessitating bed rest.
A total of 183 participants enrolled in the research project between February 2003
and June 2007 and were assessed for eligibility. Thirty-three were excluded for a variety
of reasons (see Figure 1) and 150 were randomly assigned to a treatment condition.
Among these 150, the mean age was 32.86 (SD=4.88). The majority were living with
their husband (76%), employed (61%), and had obtained a college degree (42%) or
graduate degree (33%). Participants identified primarily as Caucasian (65%), Asian
(10%), and African American (5%). Hispanic and/or Latino ethnicity represented 18% of
the sample.
Participation in the larger project involved three phases: the acute phase of
treatment, a continuation phase of treatment, and a follow-up phase. Only those women
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Figure 1. Flow of participants: Acute phase of treatment
Assessed for eligibility
N=183

Randomized
n=150

Excluded: n=33
Did not meet inclusion
criteria (20)
Went into spontaneous
remission before
randomization (2)
Did not return calls (6)
Time demand (3)
Moved (1)
Unknown (1)

Assigned to MSSG
n=49
n=150

Assigned to NSPEC
n=49
n=150

Assigned to SPEC
n=52
n=150

Did not receive assigned
intervention: n=1
Did not like treatment
assignment: 1

Did not receive assigned
intervention: n=5
Did not like treatment
assignment: 2
Pregnancy
complication: 1
Never returned calls: 1
Time demand: 1

Did not receive assigned
intervention: n=3
Pregnancy
complication: 1
Never returned calls: 1
Time demand: 1

Did not complete
treatment: n=10
-Lost to follow-up: 2
Did not return calls: 1
Moved: 1
-Discontinued: 5
Didn’t like treatment: 3
Time demand: 1
Pregnancy
complication: 1
-Delivered baby before
completing treatment: 3

Did not complete
treatment: n=11
-Lost to follow-up: 0
-Discontinued: 11
Didn’t like treatment: 4
Time demand: 2
Pregnancy
complication: 3
Moved: 1
Withdrawn for
noncompliance: 1

Did not complete
treatment: n=12
-Lost to follow-up: 1
-Discontinued: 10
Didn’t like treatment: 5
Time demand: 3
Pregnancy
complication: 1
Moved: 1
-Delivered baby before
completing treatment: 1

Completed Acute
Treatment
n=38

Completed Acute
Treatment
n=33

Completed Acute
Treatment
n=37
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who participated in the follow-up phase were included in the present study. This sample
of women is thus described in more detail below.
Participant Characteristics: Follow-up Sample
Participants who completed at least one assessment during follow-up were
included in the analyses for the present study (n=120). The 120 participants averaged
32.9 years old (SD=5.01), were predominately married (82%), employed (63%), obtained
a college education (42%) or graduate degree (35%), and reported an annual income level
of greater than $60,000 (67%). They identified primarily as Caucasian (67%), Asian
(9%), and African American (3%). Hispanic and/or Latino ethnicity represented 18% of
the sample. See Table 1 for further details related to participant information.
Clinical information related to depression history is listed in Table 2. The 120
participants experienced an average of 3.06 (SD=2.49) previous episodes of depression
and age of first onset of depression was 20.01 years (SD=9.12). Many participants had
experienced an episode of depression associated with a previous pregnancy (35%) and
the majority of participants developed the current episode of depression during pregnancy
(61%) as opposed to before pregnancy (39%). Depression rating scores at intake
included the HRSD17 (M=20.55, SD=3.30), which fell in the severe range, and the BDI-II
(M=30.16, SD=7.92), which also fell in the severe range.
Study Design and Procedure
As already indicated, although the present study focused on follow-up
participants, the larger project involved three phases. Prior to the follow-up phase, an
acute treatment phase and a continuation phase took place. Each of the three phases is
described briefly below.
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Table 1. Demographics of sample

Age (in years)
Marital Status
Married
Unmarried, live with partner
Hispanic ethnicity
Racial distribution
Native American/Alaska Native
Black or African American
Asian
White
Other
Highest education level
High school
Some college
College
Graduate school
Work status
Work
Student
Unemployed/homemaker
Household income bracket
Less than $20,000
$20,001–$59,999
More than $60,000

Randomization
n = 150

Follow-up
n = 120

32.86 (4.88)

32.90 (5.01)

75.8%
12.1%
18.1%

81.7%
8.3%
17.5%

0.7%
5.4%
10.2%
65.3%
18.4%

1.7%
3.4%
9.3%
66.9%
18.6%

4.1%
20.8%
42.3%
32.9%

2.5%
20.8%
41.7%
35.0%

61.3%
2.7%
36.0%

62.5%
2.5%
35.0%

8.1%
25.2%
66.7%

9.2%
24.2%
66.6%

Data are presented as mean, (SD), and percentages.
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Table 2. Clinical information of sample

Depression History
No. of past depressive episodes
Age of onset of first depressive episode
Patients with history of chronic depression
Patients with history of maternal depression
Depression severity at intake
Hamilton Rating Scale for Depression
Beck Depression Inventory
Length of index episode (in months)
Onset of current episode of depression
Before pregnancy
During pregnancy
Patients with history of postpartum depression
Onset during postpartum
Onset either during pregnancy or postpartum
Patients taking antidepressant medication
prior to or during pregnancy
Stopped when began trying to conceive
Stopped once pregnancy confirmed

Randomization
n = 150

Follow-up
n = 120

3.03 (2.93)
20.34 (8.78)
24.8%
46.0%

3.06 (2.49)
20.01 (9.12)
25.8%
44.1%

20.17 (4.45)
29.62 (7.91)
5.41 (5.85)

20.55 (3.30)
30.16 (7.92)
5.40 (6.20)

39.6%
60.4%

39.2%
60.8%

17.7%
31.9%

20.0%
34.8%

24.6%
9.3%
15.3%

24.4%
8.4%
16.0%

Pregnancy/Postpartum Information
Gestation week at intake
20.53 (5.75)
No. of previous pregnancies/births
2.26 (1.50)
Planned pregnancy
60.1%
Breastfed baby
Treatment postpartum (postpartum use after study)
Antidepressant use
Psychotherapy
CAM: Massage or Acupuncture

Data are presented as mean, (SD), and percentages.

20.58 (5.76)
2.18 (1.45)
63.9%
69.0%
18.3%
11.7%
6.7%
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Acute Phase of Treatment
Of the 183 participants who were enrolled in the study, 161 were eligible for
randomization, and 150 were randomized. Participants were randomly assigned to
treatment designed to specifically target acupuncture pressure points linked to the
symptoms of depression (SPEC) or to one of two control treatments: treatment using
acupuncture points which did not directly target depression-relevant patterns of
disharmony (NSPEC) or prenatal massage (MSSG). Massage was conceptualized as a
control treatment because, although it improves mood immediately after a session, there
is insufficient evidence to support its efficacy as a treatment for depression (Coelho,
Boddy, & Ernst, 2008). Participants who received acupuncture were not told which of
the two types of acupuncture they were receiving. The consent stated that, “participants
in one of these two groups will receive acupuncture that focuses on depression symptoms
and the other treatment will not.” Participants assigned to massage were not blinded to
treatment assignment. There were no significant differences between treatment groups
on expectations of benefit associated with treatment assignment. Expectancy of
treatment success was assessed after the first treatment, with one item, on a 0-5 point
Likert scale.
Among the 150 participants who were randomized to treatment, 141 began
treatment, and 108 completed treatment (77%). Participants received 12 treatments over
a period of eight weeks (two times per week for the first four weeks and weekly for an
additional four weeks) during the acute phase of treatment. See Figure 1 for a more
detailed flow of participants through the acute phase of treatment.
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Participants in the SPEC group received acupuncture treatment specifically
tailored to individually address their depression related patterns of disharmony according
to the principles of Chinese medicine and following a published standardized treatment
manual (Schnyer, Allen, Hitt, & Manber, 2001). During each session, seven to twelve
points were needled and were distributed across the same general areas of the body. The
points were selected from a set of five main points that together addressed Qi stagnation
and Shen disturbance. Other points were selected to further address differential diagnosis
and emphasize the treatment of the underlying pattern of disharmony. Within the SPEC
treatment assignment, 37/49 (76%), completed the acute phase of treatment. Attrition in
the acute phase among SPEC participants was 24%, with 12/49 participants
discontinuing.
Participants in the NSPEC group received acupuncture treatment which was also
standardized and needles were inserted in real acupuncture points that did not address
depression relevant patterns of disharmony according to traditional Chinese medicine.
The nonspecific treatment was designed to address any pertinent complaint, unrelated to
depression, presented by the participant: i.e. back ache, allergies, sciatica, etc.
Treatments also consisted of seven to twelve total points, which were distributed across
the same general areas of the body. Within the NSPEC treatment assignment, 33/44
(75%), completed the acute phase of treatment. Attrition in the acute phase among
NSPEC participants was 25%, with 11/44 participants discontinuing.
To blind treating acupuncturists, needling of the patient was separated from the
determination of which acupuncture points should be needled. Each participant was
evaluated monthly by a senior acupuncturist (assessing acupuncturist), with at least five
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years experience, who followed a standardized algorithm for assessing participants’ signs
and symptoms according to traditional Chinese medicine and designed a treatment plan
specifying the points to be needled at each session in the month that followed. The senior
acupuncturists were not told to which treatment the participant was assigned and
developed both acupuncture not specific for depression and acupuncture specific for
depression treatments for each participant. Junior acupuncturists, with less than two
years experience, provided the treatments prescribed by the senior acupuncturist. All
acupuncturists were nationally board certified (National Certification Commission for
Acupuncture and Oriental Medicine) and licensed in the state of California.
Participants in the MSSG group received prenatal massage designed to alleviate
common physical discomforts associated with pregnancy. The treatment consisted of
Swedish massage provided in a standardized fashion and included effleurage and
petrissage strokes. Approximately five minutes was spent on each of the following areas:
back, face, head, neck and shoulders, and feet while the participant was lying on her side.
The strokes were general, nonspecific, and always applied to the participants’ comfort
level. All massage therapists were California state board certified and trained in the
treatment protocol by a senior massage therapist. They were also members of the
American Massage Therapy Association. Within the MSSG treatment assignment, 38/48
(79%), completed the acute phase of treatment. Attrition in the acute phase among
MSSG participants was 21%, with 10/48 participants discontinuing.
Participants in each of the three treatment conditions received the same number of
sessions. They all followed the same schedule and the lengths of sessions were equal
(approximately 25 minutes). Treatment providers were instructed to minimize verbal
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communication and refrain from providing any counseling, dietary or other advice, or
playing background music during the treatment session.
Continuation Phase of Treatment
Upon completion of the acute phase of treatment, participants were categorized as
a responder or non-responder. Response was defined using the protocol outlined by
Frank and colleagues (1990) and Rush and colleagues (2006) (Frank et al., 1990; Rush et
al., 2006). Response was defined jointly by (a) failure to meet full criteria for MDD; (b)
at least 50% reduction from baseline HRSD17 score; and (c) HRSD17 more than 7 and less
than 14.
Responders to the acute phase of treatment entered a continuation phase during
which they received weekly treatments that continued until ten weeks postpartum.
Participants in the continuation phase received the same treatment to which they were
randomly assigned in the acute phase of treatment. Participants who did not qualify for
continuation treatment no longer received a study treatment.
Based on the number of participants who qualified for the continuation phase of
the study (70 of 108 participants), 65% of participants responded to the acute phase of
treatment. Among the 70 participants who qualified for the continuation phase of the
study, the break down across treatments was 31/49 (63%) in specific acupuncture, 16/44
(36%) in nonspecific acupuncture, and 23/48 participants in massage (48%). The number
of continuation treatments completed during pregnancy within each group was as
follows: specific acupuncture (M=3.45, SD=5.20), nonspecific acupuncture (M=4.56,
SD=5.35), and massage (M=4.57, SD=6.37). The number of continuation treatments
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completed postpartum, prior to the follow-up phase which began at ten weeks
postpartum, was as follows: specific acupuncture (M=5.94, SD=3.38), nonspecific
acupuncture (M=3.69, SD=3.60), and massage (M=5.52, SD=3.42). Among the 70
participants eligible for continuation sessions, 45 completed at least 75% of the sessions
(64%), eight completed fewer than 50% (11%), and 17 did not complete any sessions
(24%). See Table 3 for information related to number of sessions participants completed
during the continuation phase.
Follow-up Phase of Study
At the end of the continuation phase, the follow-up phase of the study began and
participants were clinically assessed at ten weeks, six months, and nine months
postpartum. Attempts were made to collect follow-up data on all participants who had
been randomized to treatment (n=150), regardless of whether they completed treatment or
participated in the continuation phase. The follow-up phase of the study was completed in
August of 2008.
A total of 120 participants completed at least one assessment during the follow-up
phase: 116 at ten weeks, 101 at six months, and 106 at nine months postpartum. The
majority of participants completed all three HRSD17 assessments during follow-up;
95/120 (79%) and 108/120 (90%) completed two or more of the HRSD17 follow-up
assessments. Only 12/120 participants (10%) completed merely one follow-up HRSD17
assessment. In terms of the number of participants completing all three BDI-II
assessments during follow-up, 69/116 (59%) completed all three, 99/116 (85%)
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Table 3. Number of participants completing each phase of the study

SPEC

NSPEC

MSSG

Total

Completed

37/49
76%

33/44
75%

38/48
79%

108/141
77%

Discontinued

12/49
24%

11/44
25%

10/48
21%

33/141
23%

Acute Phase of Treatment

Continuation Phase of Treatment
Completed
(all sessions)

21/31
68%

5/16
31%

12/23
52%

38/70
54%

Completed
(≥75% of sessions)

23/31
74%

6/16
38%

16/23
70%

45/70
64%

Completed
(≤50% of sessions)

2/31
6%

4/16
25%

2/23
9%

8/70
11%

Discontinued
(0 sessions)

6/31
19%

6/16
38%

5/23
22%

17/70
24%
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completed two or more, and 17/116 (15%) completed only one BDI-II during follow-up.
There were four participants who did not complete any BDI-II assessments, but had
completed at least one HRSD17 assessment during follow-up.
Among the 150 participants who were randomized to the acute phase of
treatment, thirty did not complete any assessments during the follow-up phase (20%). Of
the participants, 18/30 (60%) dropped out of the acute phase of treatment and completed
no further follow-up. Other reasons participants did not complete any follow-up
assessments were: refusal (n=4), not returning phone calls (n=4), pregnancy
complication resulting in no further follow-up (n=3), and investigator initiated
discontinuation from the study due to non-compliance (n=1). See Figure 2 and Figure 3
for the flow of participants during the follow-up phase, by treatment assignment and
response status, respectively.
Assessment and Measures
Schedule of Mood Assessments
During the acute phase of treatment, depression symptomatology was assessed at
baseline (prior to beginning treatment), at four weeks (halfway through treatment), and at
eight weeks (at the completion of treatment). At each of these assessments, three
depression outcome measures were given: HRSD17, BDI-II, and the major depression
episode section of the SCID-IV.
Participants qualifying for the continuation phase of treatment (responders to the
acute phase of treatment) were clinically assessed at intervals of eight weeks during their
continuation treatment and at 36 weeks gestation. Non-responders, or participants who
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Figure 2. Flow of participants: Follow-up phase of study (treatment assignment)
Randomized
N=150

Assigned to MSSG
n=49
n=150
Did not complete
follow-up, n= 4

Assigned to NSPEC
n=49
n=150
Did not complete
follow-up, n = 14

Assigned to SPEC
n=52
n=150
Did not complete
follow-up, n = 12

Pregnancy
Complication: 1
Refused follow-up: 1
Dropped out of acute
treatment: 2

Administrative
withdrawal: 1
Did not return calls: 2
Dropped out of acute
treatment: 9
Refused follow-up: 1
Pregnancy
complication: 1

Did not return calls: 2
Dropped out of acute
treatment: 7
Refused follow-up: 2
Pregnancy
complication: 1

Completed followup assessments:
n=45

Completed followup assessments:
n=35

Completed followup assessments:
n=40

10 wks postpartum:

10 wks postpartum:

10 wks postpartum:

Did not complete: 1

Did not complete: 1

Did not complete: 1

(No. completed, n=44)

(No. completed, n=34)

(No. completed, n=39)

3 mos postpartum:

3 mos postpartum:

3 mos postpartum:

Did not complete: 5
Did not return calls: 2

Did not complete: 1
Refused: 2
Did not return calls: 3

Did not complete: 3
Refused: 1
Did not return calls: 2

(No. completed, n=38)

(No. completed, n=29)

(No. completed, n=34)

6 mos postpartum:

6 mos postpartum:

6 mos postpartum:

Did not complete: 1
Did not return calls: 3

Refused: 2
Did not return calls: 4

Refused: 1
Did not return calls: 2

(No. completed, n=41)

(No. completed, n=29)

(No. completed, n=37)
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Figure 3. Flow of participants: Follow-up phase of study (response status)
Randomized
N=150
Responders to the acute
phase of treatment
n=70

Did not complete
follow-up, n= 1
Did not return calls: 1

Non-responders to the
acute phase of treatment
n=80

Did not complete
follow-up, n = 29
Did not return calls: 3
Dropped out of acute
treatment: 18
Refused follow-up: 4
Pregnancy complication: 3
Administrative withdrawal: 1

Completed followup assessments:
n=69

Completed followup assessments:
n=51

10 wks postpartum:

10 wks postpartum:

Did not complete: 2

Did not complete: 1

(No. completed, n=67)

(No. completed, n=50)

3 mos postpartum:

3 mos postpartum:

Did not complete: 3
Did not return calls: 4
Refused: 2

Did not complete: 6
Refused: 1
Did not return calls: 2

(No. completed, n=60)

(No. completed, n=42)

6 mos postpartum:

6 mos postpartum:

Refused: 2
Did not return calls: 4

Refused: 1
Did not return calls: 5
Did not complete: 1

(No. completed, n=63)

(No. completed, n=44)
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did not quality for continuation treatment, were assessed only at 36 weeks gestation. At
each of these time points, the three depression outcome measures were given: HRSD17,
BDI-II, and the major depression episode section of the SCID-IV.
During follow-up, participants were clinically assessed at intervals of twelve
weeks (three time points: ten weeks, six months, and nine months postpartum). Again, at
each of these time points, the three depression outcome measures were given: HRSD17,
BDI-II, and the major depression episode section of the SCID-IV.
Outcome Measures
Outcome measures for the current study consist of three measures of depression
which were administered at ten weeks, six months, and nine months postpartum. These
include two clinician administered assessments: the Hamilton Rating Scale for
Depression and the major depression episode section of the Structured Clinical Interview
for DSM-IV. In addition, one self-administered measure was administered: the Beck
Depression Inventory. Each of these instruments has been widely used in research for
diagnosing depression.
Hamilton Rating Scale for Depression (HRSD17). The 17-item version of the
Hamilton Rating Scale for Depression is a widely used observer-rated scale. It is
concerned primarily with the behavioral and somatic features of depression (Hamilton,
1960) and has been validated for use in postpartum populations (Thompson, Harris,
Lazarus, & Richards, 1998). The scale is clinician administered and rated. The patient is
asked to respond to questions concerning symptoms of depression that have been
experienced during the past week. Nine items include 5-point scales ranging from 0-4,
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representing ascending levels of symptom severity. The remaining eight items include 3point scales ranging from 0-2, also representing ascending levels of severity. Higher
scores indicate greater levels of depression. Interpretation of scores is as follows: less
than 7, non-depressed; 8-13, mild depression; 14-18, moderate depression; 19-22, severe
depression; more than 23, very severe depression.
The HRSD17 has demonstrated high reliability in patients with depression. Its
internal consistency has been found to range from 0.45-0.78 (Schwab, Bialon, & Holzer,
1967) and studies with depressed patients have reported high correlations (.84 and .90)
between HRSD17 scores and global clinical ratings of severity at the time of hospital
admission (Hamilton, 1960; Paykel, Prusoff, & Tanner, 1976). Interrater reliability
coefficients for the HRSD17 have been found to be 0.84 or higher (Hedlund & Vieweg,
1979). A wide range of instruments has been used to examine the convergent validity of
the HRSD17. One meta-analysis found that convergent validity of the HRSD17 with the
BDI-II ranged from 0.27 – 0.89, and 0.37 with the major depression section of the SCID
(Bagby, Ryder, Schuller, & Marshall, 2004). Lastly, two factors have emerged in
analyses: endogenous depression and agitated depression (Hedlund & Vieweg, 1979).
In the current study, the HRSD17 is the primary outcome measure of depression.
The HRSD17 was administered at baseline, following the acute phase of treatment (eight
weeks), 36 weeks gestation, ten weeks postpartum, six months postpartum, and nine
months postpartum by trained clinical interviewers who were blinded to treatment
assignment. Assessments used for the current study included those administered during
follow-up at ten weeks, six months, and nine months postpartum. The internal
consistency of the HRSD17 at intake was 0.79 and the intraclass correlation among
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clinical raters administering the HRSD17 in the current study was 0.96. During followup, participants were most frequently assessed over the phone; however, some chose to
complete the interview in person.
Structured Clinical Interview for DSM-IV (SCID). The SCID is a semistructured interview for making Axis I DSM-IV diagnoses (First, Spitzer, Gibbon &
Williams, 1994). It is administered by a clinician and includes an introductory overview
followed by modules which represent the major Axis I diagnostic classes. The output of
the SCID is a record of the presence or absence of each of the disorders being considered,
for current episode (past month), and for lifetime occurrence. The reliability of the SCID
in adult populations with diverse disorders has indicated generally high reliability (Segal,
Hersen & Van Hasselt, 1994). In an extensive multi-site project which involved testretest reliability of 592 interviews, the kappa for major depression was 0.64 (Williams et
al., 1992). In two more recent studies which examined the test-retest reliability of SCID
diagnoses, the kappas for major depression were 0.61 and 0.73 respectively (Zanarini et
al., 2000; Zanarini & Frankenburg, 2001). The SCID is also considered to have superior
validity across a number of studies examining intake diagnoses (Basco et al., 2000).
In the current study, the SCID-I clinical version was used. The clinical SCID
version is trimmed down to encompass only those DSM-IV disorders that are most
typically seen in clinical practice. The SCID-I clinical version was given at baseline to
diagnose current Major Depressive Episode (MDE) and other Axis I psychopathology.
Subsequent to baseline, the MDE module was administered following the HRSD17
assessment: following the acute phase of treatment (eight weeks), 36 weeks gestation,
and at ten weeks, six months, and nine months postpartum. Similar to the HRSD17, the
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administration of the SCID was completed by a trained interviewer who was blinded to
treatment condition. All interviewers underwent standardized training until item-level
intraclass agreement exceeded 0.85. During follow-up, participants were most frequently
assessed over the phone; however, some chose to complete the interview in person.
Beck Depression Inventory-II (BDI-II). The BDI-II is a 21 question multiplechoice self-report inventory that is one of the most widely used instruments for
measuring the severity of depression (Beck, Steer, & Brown, 1996). Each of the 21 items
corresponds to a symptom of depression and is summed to give a single score. There is a
four-point scale for each item ranging from 0 to 3. On two items (16 and 18) there are
seven options to indicate either an increase or decrease of appetite and sleep. Cut score
guidelines for the BDI-II are given with the recommendation that thresholds be adjusted
based on the characteristics of the sample, and the purpose for use of the BDI-II. A total
score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is
severe.
The BDI-II has demonstrated high reliability. Beck and colleagues (1996)
reported a coefficient alpha of 0.91 and test-retest reliability of 0.96. The same authors
also reported a positive correlation of 0.71 with the HRSD, thereby demonstrating
convergent validity. In addition, researchers have confirmed a two factor structure of the
BDI-II. The first factor, non-cognitive, consists of somatic and affective symptoms,
while the second factor, cognitive, is comprised mostly of psychological symptoms
(Steer, Rissmiller, & Beck, 2000). The BDI-II is considered to have strong content and
convergent validity. It has been found to correlate 0.71 with the HRSD (Beck, Steer, &
Brown, 1996).
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In the current study, the BDI-II was administered weekly during the acute
treatment (eight weeks) and bimonthly during the continuation treatment. It was
completed at ten weeks, six months, and nine months postpartum. Internal consistency of
the BDI-II at intake was 0.83. The patient’s response to the suicide item of the BDI-II
was always inspected on the day of its completion. Because of participants’ preference to
complete the follow-ups via phone, the BDI-II was mailed to participants and upon
completion was returned to the study coordinator.
Additional Measures and Demographic Information
Childhood Trauma Questionnaire – Short Form (CTQ-SF). The CTQ-SF is a
25-item self-report questionnaire that assesses both abuse and neglect and has three abuse
scales (physical, emotional, and sexual) (Bernstein et al., 2003). Each abuse scale
includes five items, one of which inquires broadly as to whether the respondent was
physically, emotionally, or sexually abused. At least three items on each abuse scale
inquire about specific, behaviorally defined examples of childhood abuse (e.g., for
emotional abuse, “I believe that I was emotionally abused.”). The broad items explicitly
use the term abuse and the items that inquire about specific examples of abusive
experiences are dispersed throughout the 25-item questionnaire. The item response
options of the CTQ-SF define the frequency of maltreatment experiences using a Likert
scale ranging from 0 to 5: never, rarely, sometimes, often, or very often. Bernstein et al.
(2003) have reported good internal consistency of the CTQ-SF for each of the abuse
scales across four heterogeneous samples (physical abuse, 0.83-0.86; emotional abuse,
0.84-0.89; and sexual abuse, 0.92-0.95). The CTQ-SF was mailed to participants during
follow-up to determine history of childhood abuse.
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Descriptive information obtained at baseline. The following information was
obtained at baseline and was used to describe the sample: gravidity/parity, past
obstetrical history, maternal age, planned pregnancy, presence of the father of the baby,
involvement of the father of the child emotionally and financially, health habits, client
and providers expectations about treatment (higher scores indicating greater
expectations), history of depression (e.g., number of prior depressive episodes, age at
onset of first depressive episode, history of PPD, history of depression during pregnancy,
history of maternal depression), treatment information about the current episode of
depression (e.g., antidepressant use prior to and subsequent to conception), and
socioeconomic status (see Appendix A).
Descriptive information obtained at follow-up. During the follow-up phase,
additional information was collected on the following topics: breast feeding/bottle
feeding, weight loss, alcohol consumption, smoking, prescription and nonprescription
medication use, medications taken for the treatment of anxiety or depression (including
herbal supplements), as well as other treatments for stress reduction, anxiety, or
depression (e.g. massage, rake, therapy, counseling).

CHAPTER FOUR
RESULTS
Preliminary Analyses
Participants: Follow-up Sample
The sample for the primary analyses consisted of participants for whom at least
one postpartum assessment was completed during the follow-up phase (n=120). Chi
square and analyses of variance were performed to compare demographic and clinical
characteristics of participants who completed at least one assessment during the followup phase (n=120) to participants who were randomized, but did not complete any
assessments during the follow-up phase (n=30).
In terms of demographic characteristics, there was a higher percentage of
participants married and living with their husband among those who completed a followup assessment (82%) compared to those who did not complete a follow-up assessment
(52%), χ² (3, N=149) = 13.05, p = .005. However, there were no differences between
groups on feeling emotionally supported by the father of their child, χ² (1, N=147) = 0.13,
p = .67, or feeling happy in their relationship, F(1, 147) = 0.13, p = .72. Also, although
not significant, there was a trend for participants who completed a follow-up assessment
to have a higher percentage of planned pregnancies (64%) compared to those who did not
complete a follow-up assessment (33%), χ² (1, N=148) = 3.53, p = .06. No other
significant differences were found between these groups on demographic variables.
65

66
In terms of clinical variables, several significant differences emerged between the
two groups. Participants who completed a follow-up assessment endorsed experiencing a
greater number of previous episodes of depression that began during pregnancy
compared to those who did not complete a follow-up assessment, F(1, 138) = 6.195, p =
.014. There was not a significant difference between groups on the number of previous
episodes of depression beginning in the postpartum, F(1, 140) = 1.001, p = .32. Intake
scores on the BDI-II were significantly higher for those who completed a follow-up
assessment (M=30.16, SD=7.92) compared to those who did not complete a follow-up
assessment (M=26.79, SD=3.14), F(1, 148) = 4.17, p = .043. There was not a significant
difference between groups on HSRD scores at intake, F(1, 149) = 1.64, p = .203. No
other significant differences were found between these groups on clinical variables.
Participants: Responders and Non-responders
Two groups were formed based on response status following the acute phase of
treatment: responders and non-responders. Response to treatment was defined jointly by
(a) failure to meet full criteria for MDD; (b) at least 50% reduction from baseline
HRSD17 score; and (c) HRSD17 more than seven and less than 14, at the end of the acute
treatment. Participants that did not meet the criteria for response were categorized as
non-responders. Participants who did not complete treatment were categorized based on
their last available data point. Based on this definition, the randomized sample consisted
of 70 participants who were classified as responders and 80 as non-responders. At the
end of the acute phase of treatment, responders and non-responders differed significantly
on their HRSD17 scores, F(1, 107) =96.90, p =.000, and on their BDI-II scores, F(1, 107)
=41.79, p =.000. Thus the process for determining responders and non-responders
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following acute treatment did in fact yield two different groups. Among the 120
participants included in the follow-up sample, 69 participants were categorized as
responders and 51 as non-responders.
Chi square and analyses of variance were performed to compare responders
(n=69) and non-responders (n=51) to the acute phase of treatment who were included in
the follow-up sample (n=120). There were several statistically significant differences
between the two groups. A larger percentage of responders were: (a) employed (72% vs.
49%), χ² (2, N=120) = 6.98, p = .03; (b) exclusively breastfeeding their babies
postpartum (75% vs. 55%), χ² (2, N=116) = 9.16, p = .01; and (c) randomized to SPEC
treatment (43% vs. 20%), χ² (1, N=120) = 7.52, p = .006.
Although not significant, there were two variables trending towards significance:
stopping antidepressant use after conception and endorsing a history of maternal
depression. A larger number of non-responders endorsed discontinuing antidepressant
medication following conception (24%) compared to responders (10%), χ² (1, N=119) =
3.805, p = .051, and also were more like to endorse a history of maternal depression
(53%) compared to responders (36%), χ² (1, N=118) = 3.47, p = .062. There were no
other differences found between the responders and non-responders included in the
follow-up sample, on other demographic or clinical variables (see Table 4).
Measures
Preliminary analyses were completed to examine the correlations between BDI-II
and HRSD17 scores at each of the three postpartum time points. The correlation between
the BDI-II and HRSD17 at ten weeks postpartum was, r(106)=0.677, p=.000; at three
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Table 4. Clinical information of responders and non-responders
Responders
n = 69
Depression History
No. of past depressive episodes
Age of onset of first depressive episode
Patients with history of chronic depression
Patients with history of maternal depression
Depression severity at intake
Hamilton Rating Scale for Depression
Beck Depression Inventory
Length of index episode (in months)
Onset of current episode of depression
Before pregnancy
During pregnancy
Patients with history of postpartum depression
Onset during postpartum
Onset either during pregnancy or postpartum
Patients taking antidepressant medication
prior to or during pregnancy
Stopped when began trying to conceive
Stopped once pregnancy confirmed
Pregnancy/Postpartum Information
Gestation week at intake
No. of previous pregnancies/births
Planned pregnancy
Breastfed baby
Treatment postpartum (postpartum use after study)
Antidepressant use
Psychotherapy
CAM: Massage or Acupuncture
Treatment Assignment
SPEC
NSPEC
MSSG

Data are presented as mean, (SD), and percentages.

Non-responders
n = 51

3.26 (2.78)
20.76 (9.21)
27.5%
36.2%

2.78 (2.02)
18.98 (8.98)
23.5%
52.9%

20.09 (3.21)
29.26 (7.47)
5.49 (7.68)

21.18 (3.34)
32.02 (7.27)
5.27 (3.16)

42.0%
58.0%

35.3%
64.7%

21.7%
37.9%

15.7%
30.6%

18.8%
8.7%
10.1%

31.4%
7.8%
23.5%

21.15 (5.97)
2.24 (1.51)
68.1%
75.4%

19.80 (5.44)
2.10 (1.39)
56.9%
54.9%

15.9%
10.1%
7.2%

21.6%
13.7%
9.8%

43.4%
23.2%
33.3%

19.6%
37.3%
43.1%
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months postpartum, r(88)=.0.732, p=.000; and at six months postpartum, r(84)=0.711,
p=.000. The two scales were significantly correlated at each time point suggesting strong
convergent validity. Additionally, each measure was highly correlated with itself across
the three time points (see Table 5).
Acute Treatment Response and Postpartum Depression
It was hypothesized that, regardless of assigned treatment modality, early
successful treatment of depression during pregnancy would incur protection against
postpartum depression. More specifically, hypothesis 1(a) predicted that responders to
the acute phase of treatment during pregnancy would have better clinical outcomes on the
HRSD17 at ten weeks, six months, and nine months postpartum compared to those who
did not respond to the acute phase of treatment. Hypothesis 1(b) predicted that
responders to the acute phase of treatment would have lower depressive symptom
severity scores on the BDI-II at ten weeks, six months, and nine months postpartum
compared to non-responders to the acute phase of treatment. Tables 6 and 7 present
descriptive data for the HRSD17 and BDI-II, respectively, across the three postpartum
time points.
Mixed model regression analyses were used to test for differential effects of
response to treatment on the main outcome measure (Hamilton Rating Scale for
Depression) and separately using the self-report symptom severity measure (Beck
Depression Inventory) using follow-up data provided at ten weeks, six months and nine
months postpartum. In the mixed effects analyses, the following variables were included
as fixed effects: response status (responders, non-responders), time (ten weeks, six
months, and nine months postpartum), and the response status by time interaction.
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Table 5. Correlation coefficients: HRSD17 and BDI-II across the postpartum phase
Variable
1. BDI-II

1.

2.

3.

4.

5.

-------

10 weeks postpartum
2. BDI-II

0.695**

-------

0.637**

0.782**

-------

0.677**

0.505**

0.513**

-------

0.620**

0.732**

0.607**

0.614**

-------

0.323**

0.506**

0.711**

0.289*

0.537**

6 months postpartum
3. BDI-II
9 months postpartum
4. HRSD17
10 weeks postpartum
5. HRSD17
6 months postpartum
6. HRSD17
9 months postpartum
** p≤.001, * p≤.005
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Table 6. Mean HRSD17 scores during the postpartum

10 weeks
postpartum
N=116

6 months
postpartum
N=101

9 months
postpartum
N=106

6.51 (5.78)
n= 116

6.87 (5.96)
n= 101

7.32 (5.24)
n= 106

Responder

5.88 (5.12)
n= 66

5.93 (5.39)
n= 60

7.19 (5.14)
n= 62

Non-Responder

7.34 (6.52)
n= 50

8.24 (6.54)
n= 41

7.50 (5.44)
n= 44

Follow-up Sample

Response Status:

Treatment v. Collapsed Control:
SPEC

7.25 (5.23)
n= 39

6.18 (4.90)
n= 34

6.57 (4.87)
n= 37

Control

6.13 (6.04)
n= 77

7.22 (6.44)
n= 67

7.72 (5.42)
n= 69

Data are presented as mean and (SD).
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Table 7. Mean BDI-II scores during the postpartum
10 weeks
postpartum
N=109

6 months
postpartum
N=89

9 months
postpartum
N=86

9.66 (7.32)
n= 109

9.93 (8.69)
n= 89

10.09 (7.93)
n= 86

Responder

7.55 (5.95)
n= 63

8.31 (8.18)
n= 56

9.39 (7.58)
n= 49

Non-Responder

12.56 (8.07)
n= 46

12.70 (8.95)
n= 33

11.02 (8.40)
n= 37

Follow-up Sample

Response Status:

Treatment v. Collapsed Control:
SPEC

9.02 (6.43)
n= 35

9.41 (8.13)
n= 34

9.81 (6.89)
n= 31

Control

9.96 (7.73)
n= 74

10.26 (9.07)
n= 55

10.25 (8.52)
n= 55

Data are presented as mean and (SD).
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Mixed effects models allow flexible modeling of the covariance structure of data
and thus can adequately model data in which observations are not independent. They are
also less restrictive in that they can be applied to repeated measurements taken at unequal
(between and within subjects) time intervals (Charkroborty & Gu, 2009). Mixed models
provide a contemporary approach to missing data by using estimated individual time
trend lines based on all available data for each individual, augmented by information
from data for all other individuals in the sample (Gibbons et al., 1993). These analyses
were completed using Predictive Analytics SoftWare (PASW) SPSS Version 18.
First, mixed effects analyses tested hypothesis 1(a) by examining Hamilton
Rating Scale for Depression scores at ten weeks, six months, and nine months postpartum
based on response status (responder or non-responder) to the acute phase of treatment.
There was not a significant response status by time interaction, F(1, 116) =.97, p =.327
nor was there a significant main effect for time, F(1, 116) =.99, p =.320. Although
trending towards responders faring better in the postpartum phase, there was not a
significant main effect for response status in this analysis, F(1, 118) =2.80, p =.097.
Thus, hypothesis 1(a) with regard to clinical outcome, as measured by the HRSD17, was
not supported.
Second, hypothesis 1(b) was tested using a similar analysis to examine Beck
Depression Inventory scores at ten weeks, six months, and nine months postpartum based
on response status (responder or non-responder) to the acute phase of treatment. There
was not a significant response status by time interaction, F(1, 90) =1.99, p =.162,
suggesting little change in slope over time between responders and non-responders on
self-reported depression symptom scores. There was also not a significant main effect for
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time, F(1, 90) =.024, p =.877. However, there was a significant main effect for response
status such that responders endorsed fewer depressive symptoms on the BDI-II compared
to non-responders, F(1, 113) =13.37, p =.000.
In order to test if treatment during continuation was driving the significant main
effect for response status, two covariates were added to the mixed effects model: number
of continuation treatment sessions during pregnancy and number of continuation
treatment sessions during the postpartum phase. The main effect for response status
remained significant; responders reported lower depressive symptoms severity scores on
the BDI-II in the postpartum phase compared to non-responders, even when controlling
for number of continuation treatment sessions during pregnancy and number of
continuation treatment sessions during the postpartum phase, F(1, 120) =7.20, p =.008.
This finding supported the hypothesis that participants who responded to acute treatment
would have lower depression symptom severity scores during the postpartum compared
to non-responders, as measured by the BDI-II.
Finally, although there was not a significant main effect for HRSD17 scores across
the postpartum, there was some evidence that treatment assignment may have been
influencing this result. In examining the observed means for HRSD17 scores (see Table
6), responders’ scores appeared to be increasing over time whereas non-responders’
scores were not. However, the observed HRSD17 means for treatment assignment
indicated that the SPEC group was remaining consistent across time, whereas the
combined control group was worsening (increasing HRSD17 scores). Based on this
observation, it appeared that among responders, different patterns of scores may have
emerged based on treatment assignment to SPEC or control. A post-hoc analysis was
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completed to test this observation. A mixed effects analysis was limited to responders,
and examined Hamilton Rating Scale for Depression scores at ten weeks, six months, and
nine months postpartum based on treatment assignment (SPEC or control). There was a
significant treatment assignment by time interaction, F(1, 64) =4.29, p =.04, which
suggested that although the control group had lower scores at the first postpartum time
point, ten weeks, their scores worsened across the postpartum phase while the SPEC
group maintained improvement (see Figure 4).
Treatment and Relapse Rate
It was expected that a subset of women would experience re-occurrence of MDD
during the postpartum phase. More specifically, hypothesis two predicted that time to
relapse, following remission, would be sooner for participants in the control groups
(NSPEC and MSSG) than for participants in the SPEC group when examined at ten
weeks, six months, and nine months postpartum. Responders were classified as being in
remission if the following two criteria were met jointly: a) the absence of the core
symptoms of depression being reported at threshold or subthreshold level using the SCID
(depressed mood and anhedonia); and, b) HRSD17 score of seven or less. Rate of relapse
was determined based on SCID criteria and included any participant who met criteria for
MDD at any one of the three follow-up time points (ten weeks, six months or nine
months postpartum).
It was proposed that the differential likelihood of relapse would be analyzed via
survival analysis using the Cox proportional hazards method, which models event rates as
a log-linear function of predictors, or covariates. However, this analysis was not
performed because among the 65 participants who remitted from their index episode of
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Figure 4. Mean HRSD17 scores among responders: Treatment assignment by time
interaction (p=.04)

10
9
8
SPEC

7

Combined Controls

6
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MDD by 36 weeks gestation only four (6%) relapsed during the postpartum phase. In
order to arrive at reliable estimates of survival and standard errors at each time interval,
the minimum recommended sample size is 30, thus precluding a test of the second
hypothesis (time to relapse following remission).
It should be noted that, although few met strict criteria for MDD following
remission, descriptive statistics for other variables suggest some re-emergence of
depressive symptoms. One such variable is having a score ≥ 14 on the HRSD17 during
the postpartum phase, which was the minimum HRSD17 score required for inclusion in
the study; 13 of the 65 (20%) scored ≥ 14 on the HRSD17 during the postpartum phase,
suggesting sub-criteria depressive symptomatology. Additionally, 7 of the 65
participants (11%) who remitted began taking antidepressant medication during the
postpartum phase which may also suggest return of depressive symptoms.
Predictors of Postpartum Depression
The current study expected to replicate previous research indicating increased risk
for postpartum depression. Three variables measuring history of depression were tested:
having ever experienced a previous episode of depression, having a history of depression
during pregnancy, and previous episodes of postpartum depression. Hypothesis 3(a)
predicted that women with a previous history of depression would be more likely to meet
criteria for MDD during the postpartum phase (at ten weeks, six months, or nine months
postpartum). The relationship between prior history of depression and the absence or
presence of MDD during postpartum was analyzed using Chi square. The analysis was
completed by generating two categorical variables: the presence of MDD (yes/no) at any
time point during the postpartum and prior history of depressive episodes (none/some).
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Only nine participants did not have a past history of depression and few
participants experienced MDD during the postpartum (n=20); therefore, Fisher’s exact
test was utilized for this analysis as it does not assume cell values have an expected
frequency of five or greater and is typically used for a 2x2 table. In this analysis, there
was not a significant difference between previous history of depression and presence or
absence of MDD during the postpartum phase, χ² (1, N=109), p = .48. Thus, hypothesis
3(a) was not supported.
Hypothesis 3(b) predicted that a greater number of past episodes of depression
during pregnancy and postpartum would be associated with higher depression symptom
severity scores as measured by the HRSD17 at six months and nine months postpartum.
The relationship between number of past depressive episodes during pregnancy and the
postpartum phase and symptom severity at six and nine months postpartum was analyzed
using Spearman’s correlation. Two separate correlations were computed. Spearman’s
correlation was computed for HRSD17 scores at six months and nine months postpartum
with both number of past episodes of depression during pregnancy and past number of
episodes of postpartum depression (see Table 8).
HRSD17 scores at six months postpartum were significantly correlated with
number of previous episodes of depression during pregnancy, r(97)=.264, p=.008.
Similarly, HRSD17 scores at six months postpartum were significantly correlated with
number of previous episodes of postpartum depression, r(96)=.286, p=.004. However, at
nine months postpartum, HRSD17 scores were not significantly correlated with number of
previous episodes during pregnancy, r(102)=.089, p=.370, or with number of previous
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Table 8. Correlation coefficients: HRSD17 postpartum and depression history
Variable

1.

2.

3.

4.

1. HRSD17 6 months postpartum

-------

2. HRSD17 9 months postpartum

.422**

-------

3. Number of previous episodes of
depression during pregnancy

.264*

.089

-------

4. Number of previous episodes of
postpartum depression

.286*

.090

.590**

-------

5. Number of previous episodes of
depression

.179

-.110

.184

.272*

** = p<.001; * = p<.01
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episodes of postpartum depression, r(101)=.090, p=.367. The two predictor variables,
history of depression during pregnancy and history of postpartum depression, were highly
correlated, r(139)=.590, p=.000, suggesting significant overlap among the two variables.
These findings support the hypothesis that participants with histories of depression during
pregnancy and/or postpartum would experience greater depression symptom severity
scores at six months postpartum; however, by nine months postpartum the predictive
relationship did not hold.
Exploratory Analyses: ROC Curve Approach
Exploratory analyses to examine potential predictors of postpartum depression
utilized the receiver operating characteristic (ROC) curve approach with the ROC4
program (Kraemer, 2004). ROC is a nonparametric technique that evaluates multiple
potential predictors without making restrictive assumptions (e.g., linearity, additivity,
homoscedasticity) that are required of parametric linear models. A unique feature of the
ROC program is that it allows the user to designate the criterion for identifying the best
variable by adjusting the weight in kappa in order to optimize sensitivity (i.e., emphasis
placed on avoiding false negatives), specificity (i.e., emphasis placed on avoiding false
positives), or efficiency (i.e., equal emphasis placed on both types of errors). The
decision to adjust the weighted kappa is based on clinical importance of false negatives
vs. false positives. For each independent variable (IV), the program searches for a cutpoint that optimizes the balance between sensitivity and specificity for predicting the
outcome of interest (e.g., postpartum depression). The groups identified in each round of
the analysis are then re-tested to see which variable best predicts outcome within that
group, until groups are too small for significant predictors to be found (p > 0.01). This
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hypothesis-generating technique has been used in other naturalistic studies as it is well
suited for identifying predictors or characteristics of those at risk for a particular
dichotomous outcome, such as postpartum depression (Ackerman, Greenland, &
Bystritsky, 1996; Manber et al., 2008; O’Hara et al., 2002).
In the present study, two separate ROC analyses were conducted. In the first, the
criterion variable was HRSD17 ≥ 14 (yes / no), at any of the following three postpartum
time points: ten weeks, six months, and nine months postpartum. The cutoff of HRSD17
≥ 14 is common in the depression literature and was used as one of the inclusion criteria
in this study. In the second ROC analysis the criterion variable was meeting MDD
criteria on the SCID at any of the same three time points: ten weeks, six months, and nine
months postpartum. Thus, the two analyses served to identify predictors of depressive
symptom severity, and separately, clinical diagnoses of MDD during the postpartum. In
the ROC analysis, the weight for kappa was set at 0.50 so that false negatives and false
positives were given equal consideration.
The predictors (IVs) entered into the model included treatment group, response to
acute treatment, income level, planned pregnancy (yes/no), number of previous
depressive episodes, number of previous pregnancies, HRSD17 score at baseline, HRSD17
score at the end of pregnancy (36 weeks gestation), breast / bottle feeding, emotional
support from father of the child, relationship satisfaction with father of the child, client
expectations of treatment benefits, provider expectations of treatment benefits, receiving
depression treatment postpartum, four subscales of the CTQ (childhood physical neglect,
childhood emotional neglect, childhood emotional abuse, childhood physical abuse),
history of maternal depression, age, age of onset of first depressive episode, whether
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antidepressants were stopped when planning to conceive, and whether antidepressants
were stopped following conception (consistent with the exclusion criteria, no study
participants used antidepressants subsequent to enrollment, but may have taken an
antidepressant earlier in pregnancy).
The results of the ROC analysis for HRSD17 score ≥ 14 (yes/no) during the
postpartum period (n=120) are depicted in Figure 5. Three significant predictors were
identified. At the first level, the best predictor variable was HRSD17 score at 36 weeks
gestation with an optimal cut-point of 11, χ² =7.46, p < .01. Of the 42 participants who
scored ≥ 11, 40.5% experienced clinically significant depressive symptoms at some point
during the postpartum. This group was further differentiated by client expectation of
treatment benefits (CE), with a cut-point of client expectation < 3.75, χ² = 9.89, p < .01.
Of the 21 participants who scored 11 or more on the HRSD17 at the end of pregnancy and
also had low expectations of benefits early in treatment (< 3.75), 61.9% experienced
clinically significant depressive symptoms during the postpartum. In contrast, of the 17
participants who scored 11 or more on the HRSD17 at the end of pregnancy but had high
expectations of benefits early in treatment (≥ 3.75), only 11.8% experienced clinically
significant depressive symptoms during the postpartum. Of the 61 participants whose
HRSD17 score at 36 weeks gestation was < 11 and also scored ≥ 15 on the emotional
abuse subscale of the CTQ, 45.5% experienced clinically significant depressive
symptoms during the postpartum. In contrast, of the participants who scored < 11 on the
HRSD17 at 36 weeks gestation and < 15 on the emotional abuse subscale of the CTQ,
only 11.6% experienced clinically significant depressive symptoms during the
postpartum. No other significant variables were found.
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Figure 5. ROC tree of subgroups with different risk for experiencing HRSD17 scores ≥ 14
in the postpartum phase. The number of participants who meet criteria are denoted in
parentheses.
N = 120 participants
25% HRSDPP ≥ 14
(30)
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Thus, the ROC analysis identified HRSD17 score at 36 weeks gestation as the best
predictor of experiencing an HRSD17 score ≥ 14 during the postpartum phase. For those
who met this initial cut-point (HRSD17 at 36 weeks ≥ 11), the next best predictor was
client expectations of their assigned treatment, such that more favorable expectations (≥
3.75) resulted in better outcomes. For those who did not meet the initial cut-point
(HRSD17 at 36 weeks < 11), the next best predictor was childhood emotional abuse, such
that higher levels of emotional abuse (EA ≥ 15) resulted in greater likelihood of
experiencing an HRSD17 score ≥ 14 during the postpartum phase.
A second ROC analysis was completed using SCID criteria for MDD (yes/no)
during the postpartum as the criterion variable (n=120). This exploratory analysis
revealed two predictors (see Figure 6 for ROC tree). At the first level, the best predictor
was stopping antidepressant use after conception (and prior to beginning the study), χ² =
13.77, p < .001. Of the 16 participants who stopped an antidepressant after conception,
50% met criteria for MDD during the postpartum. For this small group, the stopping rule
went into effect and the ROC analysis did not further differentiate any subgroups. In
contrast, out of the 100 participants who never used an antidepressant during pregnancy,
only 13% met criteria for MDD during the postpartum. Subsequently, this group was
further differentiated by the severity of depressive symptoms at baseline, with a cut-point
of intake HRSD17 ≥ 25, χ² = 9.91, p < .01. Of the 12 participants who did not use
antidepressants during pregnancy and had intake HRSD17 scores ≥ 25, 41.7% met criteria
for MDD during the postpartum. In contrast, of the 88 participants who did not use
antidepressants during pregnancy and had intake HRSD17 scores < 25, only 9.1% met
criteria for MDD during the postpartum. No other significant variables were found.
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Figure 6. ROC tree of subgroups with different risk for meeting SCID criteria for Major
Depression in the postpartum phase. The number of participants who meet criteria are
denoted in parentheses.
N = 120 participants
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In summary, this second exploratory analysis using ROC indicated that the best
predictor for meeting MDD criteria postpartum was stopping antidepressant use after
conception. For participants who had not taken an antidepressant medication during
pregnancy, the next best predictor was intake HRSD17 score, with higher scores (≥ 25)
resulting in a greater likelihood of meeting criteria for MDD postpartum.

CHAPTER FIVE
DISCUSSION
Introduction
The current project examined the impact of treating major depressive disorder
during pregnancy to reduce the likelihood of postpartum depression and explored factors
that predict postpartum depression in a high-risk sample. The results partially support the
hypothesis that successful treatment of depression during pregnancy can reduce
depressive symptom severity in the postpartum phase. The results also provide
replication of previously identified predictors of postpartum depression, including a
strong emphasis on depressive symptoms during pregnancy increasing risk in the
postpartum. In combination, the findings suggest women at risk for postpartum
depression may be identified during pregnancy and successful treatment prior to birth
may reduce the occurrence of postpartum depressive symptomatology.
Acute Treatment Response and Postpartum Depression
It was hypothesized that responders to the acute phase of study treatment, during
pregnancy, would benefit from enduring effects of their treatment into the postpartum
phase. In other words, successful treatment of depression during pregnancy would incur
protection against postpartum depression. This hypothesis was tested using mixed effects
modeling, analyzing both BDI-II and HRSD17 data. The results partially supported the
proposed hypothesis.
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Depression symptom severity scores in the postpartum, as measured by the selfreported BDI-II, were significantly lower for responders to the acute phase of treatment
compared to non-responders. This suggests that participants who responded to treatment
endorsed fewer depressive symptoms in the postpartum phase. When examining clinical
status scores in the postpartum phase, as measured by the HRSD17, there was not a main
effect for response status. However, the analysis was trending towards significance, such
that responders had better clinical outcomes postpartum. This trend, although not
statistically significant, mirrors the finding associated with the BDI-II data. Taken
together, these results suggest that successful response to treatment during pregnancy
may provide enduring effects into the postpartum phase, up to nine months in the current
study, which is supportive of the main hypothesis of this project. Before discussing
possible reasons for the inconsistent findings with respect to the BDI-II and HRSD17, the
available literature on the effects of response to treatment during pregnancy and
depressive symptom severity during the postpartum will be addressed.
To date, the majority of studies examining treatment interventions for postpartum
depression are implemented during the postpartum phase. Among these, medication,
alone or with CBT; interpersonal therapy; and CBT produce the largest effect sizes
(Bledsoe & Grote, 2006). Few studies have examined whether treatment during
pregnancy can have a lasting effect into the postpartum. Among the existing published
studies, many have provided group psychoeducation classes, as opposed to
psychotherapeutic intervention, and others inherently exclude medication, which may
result in lower effect sizes. Two studies provided IPT during pregnancy to depressed
women and included maintenance sessions postpartum. These studies demonstrated
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lasting effects up to six months postpartum (Grote et al., 2004; Grote et al., 2009). The
current study results are consistent with the previous findings associated with IPT, even
while controlling for continuation sessions both during pregnancy and postpartum, which
is noteworthy given the women who responded to treatment predominately stayed well
through nine months postpartum. The current results provide further evidence that timing
of implementation of interventions during pregnancy, as well as response to treatment
regardless of treatment assignment, may produce enduring effects in the postpartum
phase.
Lastly, although responders in the current study were comprised of participants
among all three treatment groups, post-hoc analyses limited only to responders, provided
evidence that the active treatment may have contributed to the maintenance of change
postpartum. Among HRSD17 responders, there was a significant interaction based on
treatment group assignment across time in the postpartum. While responders assigned to
the control treatments began with lower HRSD17 scores at ten weeks postpartum
compared to responders to SPEC, across the postpartum phase SPEC responders’
HRSD17 scores remained consistent, whereas the responders assigned to one of the
control treatments experienced a worsening of symptoms over time.
This interaction effect is consistent with the findings of both Manber et al.’s
(2004) pilot study and Manber et al.’s (2010) larger randomized clinical trial examining
the efficacy of treating depressed pregnant women with acupuncture. Both studies found
a greater rate of decrease in depression symptom severity and a greater response rate for
the acupuncture specific for depression (SPEC) compared to control groups following the
acute phase of treatment (Manber et al., 2004; Manber et al., 2010). The current finding

90
builds upon these earlier results in that responders assigned to SPEC maintained their
improvement on HRSD17 scores across the postpartum time frame compared to
responders assigned to the control groups. In sum, this suggests that not only was
response to treatment important for reducing postpartum depressive symptoms, but also
successful treatment with the active treatment, SPEC, was influential in maintenance of
change and improvement up to nine months postpartum. Thus, the current research
provides preliminary evidence that successful treatment with acupuncture may provide
protection against reemergence of mood symptoms postpartum.
BDI-II and HRSD17 Differences
The differences in statistical significance between the BDI-II and HRSD17 mixed
effects analyses might be explained in a number of ways. First, the BDI-II and HRSD17
vary in administration. The BDI-II is a self-report measure and the HRSD17 a clinician
administered rating. Research has indicated that the prevalence of depression may vary
systematically as a function of the method used to identify depression cases.
Self-report measures introduce the possibility of participant bias. This may
present as an exaggeration of symptoms by participants, compared to objective
measurements in which trained clinicians provide ratings; however, it is also possible
participants might underreport symptoms. It has been hypothesized that self-report
measures may identify a broader spectrum of depressive disorders or symptoms that
reflect comorbid psychiatric illness (e.g., anxiety) or general distress whereas clinician
administered ratings adhere to strict guidelines when determining whether or not a
symptom is rated. In the current study, responders tended to rate fewer postpartum
depressive symptoms on the BDI-II, a self-report measure, whereas on the HRSD17,
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responders and non-responders did not significantly differ. This suggests that
participants perceived themselves as less depressed than the clinician.
In addition to participant bias, it is possible that response bias may have
influenced the results. The BDI-IIs were predominately sent by mail during the followup phase whereas HRSD17 assessments were completed over the phone. As a result,
there were fewer BDI-IIs completed at each time point in the postpartum compared to
HRSD17 assessments. There were no significant differences in HRSD17 scores during
follow-up between those who returned the BDI-II and those who did not at 10 weeks
(p>.509), six months (p>.946), and nine months postpartum (p>.939), suggesting a lack
of difference in patterns of response between the two groups, and giving greater
confidence to the overall main effect found when examining BDI-II scores using mixed
effects analyses.
Second, while both are measures of depression, the BDI-II and HRSD17 assess
slightly different dimensions of a multi-dimensional construct. The HRSD17 focuses
primarily on behavioral and somatic symptoms of depression, while the BDI-II includes a
large focus on cognitive aspects of depression. The HRSD17 assesses symptoms such as
early, middle, and late insomnia; psychomotor retardation; agitation; loss of appetite and
weight loss; and muscular aches and pains. There is less emphasis on cognitive factors
influencing depressive symptomatology on the HRSD17 compared to the BDI-II.
Although the two measures may tap slightly different dimensions of depression, they tend
to be highly correlated (Beck et al., 1996). Consistent with the literature, in the current
study the BDI-II and HRSD17 were highly correlated with each other at each of the three
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postpartum time points: ten weeks postpartum (0.68), six months postpartum (0.73), and
nine months postpartum (0.71).
Furthermore, the BDI-II has been consistently found to consist of two factors:
somatic and cognitive. Research examining the factor structure of the BDI-II in a nonclinical pregnancy sample found a two factor solution explained 43% of the variance with
somatic and cognitive factors contributing equally (Carvalho Bos et al., 2009). However,
a three factor solution was preferred during the postpartum, explaining 50% of the
variance, and included a factor for guilt in addition to somatic and cognitive factors.
Moreover, research has indicated that women with postpartum depression appear to be
significantly more likely than nonpostpartum women to present with anxious features
(Hendrick, Altshuler, Strouse, & Grosser, 2000), and during pregnancy, somatic
symptoms such as appetite increase, sleep disruption, and agitation have been found to be
uninformative with regard to a MDD diagnosis (Yonkers et al., 2009). In fact, Spinelli
and Endicott’s (2003) controlled clinical trial testing the efficacy of IPT during
pregnancy excluded the somatic cluster from the BDI-II, as it did not reduce the
psychometric stability of the BDI-II in this patient population, and the cognitive cluster of
symptoms on the BDI-II was most sensitive to depression during pregnancy.
Extrapolating from these findings, it may be that in the current study responders
fared better than non-responders as measured by the BDI-II based on enduring effects
related to cognitive aspects of depression as opposed to somatic. Post-hoc analyses using
mixed effects analyses to examine changes in the cognitive cluster of items on the BDIII, across the three postpartum time points, revealed responders to treatment endorsed
fewer cognitive based depressive symptoms compared to non-responders, even when
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covarying for number of continuation sessions during pregnancy and postpartum, F(1,
120) =8.11, p =.005. A main effect for the somatic cluster of BDI-II items across the
three postpartum time points was also significant, such that responders endorsed fewer
somatic depressive symptoms postpartum, with continuation sessions during pregnancy
and postpartum included as covariates, F(1, 120) =4.56, p =.04. However, in comparison
to the cognitive factor the significance was not as strong. This trend suggests that while
responders experienced fewer cognitive and somatic depressive symptoms postpartum
compared to non-responders, the difference in somatic symptoms between the groups was
not as large. Thus, somatic symptoms may remain higher in both responders and nonresponders in the postpartum phase based on recovery from birth, delivery, and lasting
somatic concerns related to changes in sleep, appetite, and fatigue.
Influence of Remission on Enduring Response Effect
While responders endorsed fewer depressive symptoms during follow-up
compared to non-responders, the long-term outcomes for treatment during pregnancy and
postpartum are not well characterized. Depression runs a chronic course in which relapse
and recurrence rates following treatment are high (Solomon et al., 2000). A metaanalysis completed by Vittengl et al. (2007) found that among responders to cognitive
behavior therapy, 29% experienced a relapse or recurrence by the end of the first year
following treatment. In a high-risk pregnancy sample, Cooper et al. (2003) found that the
effects of therapeutic treatment (compared with usual care) faded within about five
months. The postpartum period presents significant challenges to women as they balance
infant care with responsibilities in the home and at work. Despite these challenges,
women in the current study tended to remain well in the postpartum phase.
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In fact, the rates of depression as measured by both the BDI-II and HRSD17,
regardless of response status, fell in the minimal range during the postpartum phase
suggesting overall improvement on depression scores compared to during pregnancy.
The overall decline in depression symptom severity scores from pregnancy and
maintained throughout the postpartum may be attributable to continued rates of recovery
among those who did not respond to the acute treatment. Alternatively, these findings
may simply reflect the episodic course of depression whether or not it is treated (Solomon
et al., 2000) or may also reflect accelerated improvement over time independent of
recovery following acute treatment. Whether participants improved following pregnancy
due to remission or due to the effects of their treatment, overall women in this project
remained well during the postpartum phase, despite facing challenges which might
undermine the sustainability of recovery.
Treatment and Relapse Rate
It was hypothesized that a subset of women would experience re-occurrence of
MDD in the postpartum and specifically, that time to relapse would be sooner for
participants in the control groups (NSPEC and MSSG) than for participants in the SPEC
group. In the current study, few women experienced re-occurrence of MDD during the
postpartum phase; therefore, a survival analysis testing differential likelihood of relapse
was not tested.
Among the 65 who remitted from their index episode of MDD by 36 weeks
gestation, 6% (4/65) met criteria for MDD postpartum, 20% (13/65) scored ≥ 14 on the
HRSD17 postpartum, and 11% (7/65) began taking antidepressant medication postpartum.
The incidence of postpartum depression in the current study is similar to rates reported in
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the literature, which range from 3.5% to 17%. However, given this was a high-risk
sample and that the probability of relapse among patients with MDD in the general
population after six months is nearly 30% (Keller et al., 1983), it was anticipated that a
larger group of women would experience re-occurrence of MDD postpartum.
The lack of re-occurrence in the postpartum may be due to a number of reasons.
The current sample consisted of women with high levels of education (35% obtained a
graduate degree), were largely employed (63%), and reported a household income greater
than $60,000 (67%) and therefore have had both the resourcefulness and finances to
access support in the postpartum phase to balance the responsibility of infant care with
work and family. Additionally, some women sought treatment for depression during the
postpartum phase including antidepressant medication (18%), psychotherapy (12%), and
massage and/or acupuncture (7%), which have likely reduced depressive symptoms.
Furthermore, the sample consisted of women who identified as living with their husband
(82%) or with the father of their child (8%). Given the increasing rates of births to single
mothers, and their associated stressors, the fact that 90% of the women in the current
study were in committed relationships with the father of their child may have resulted in
increased benefit from emotional support and a sense of stability. Another source of
support for the participants may have been the continuous attention they received through
their involvement in the study. These factors may have improved outcomes. Finally,
while research points to a continuity of depressive symptoms from pregnancy into the
postpartum phase, it also documents a decrease in depressive symptoms from pregnancy
to the postpartum period (Evans et al, 2001). This pattern is similar to the reduced rates
of depression following birth in the current project.
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Predictors of Postpartum Depression
It was hypothesized that previously identified predictors of postpartum depression
including a history of depression during pregnancy and a previous episode of postpartum
depression would emerge as significant predictors in the current study. The results were
largely consistent with this hypothesis and replicated findings in the literature related to
predictors of postpartum depression. Spearman’s correlations indicated that both number
of previous episodes of depression during pregnancy and number of previous episodes of
postpartum depression were significantly correlated with HRSD17 scores at six months
postpartum. This finding is consistent with previous research that has demonstrated
depression during pregnancy is one of the strongest predictors of postpartum depression
(Milgrom et al., 2008; Verkerk et al., 2003) and that previous episodes of postpartum
depression increase the risk for future postpartum episodes (Wisner et al., 2004).
While the correlations among number of previous episodes of depression during
pregnancy and number of previous episodes of postpartum depression were significantly
correlated with HRSD17 scores at six months postpartum, they did not demonstrate
statistical significance at nine months postpartum. Research has indicated that the timing
of onset of postpartum depression tends to cluster closer to birth, and 90% of women
experience onset within 28 weeks postpartum (Wisner et al., 2004); therefore, it is
possible that by nine months postpartum there were fewer depression symptoms
emerging, thereby decreasing the likelihood of finding statistically significant positive
correlations. Additionally, over half of infants are sleeping concurrently with their
parents at five months old (Henderson, France, Owens, & Blampied, 2010) and because
sleep and mood are highly correlated, it is possible that improved sleep may have also
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resulted in reduced depressive symptomology at nine months postpartum. Overall, the
findings are consistent with the literature and suggest that previous history of depression,
occurring during pregnancy and the postpartum, places a woman at greater risk for
experiencing postpartum depression following a future pregnancy.
Exploratory Analyses: ROC Curve Approach
Exploratory analyses were completed to identify characteristics of women who
were at risk for experiencing clinically significant depression symptoms postpartum
(HRSD17 ≥ 14 during the postpartum phase). Overall, the findings revealed that greater
depression symptoms in late pregnancy (36 weeks gestation) increased the likelihood of
experiencing depression in the postpartum phase. Furthermore, low client expectations
of their treatment assignment during the acute phase and childhood emotional abuse also
emerged as significant predictors. More specifically, the ROC analysis revealed that
participants who scored ≥ 11 on the HRSD17 assessment (mild depression) at 36 weeks
gestation were more likely to experience clinically significant depressive symptoms
postpartum. Among participants who scored at least 11 on the HRSD17 at 36 weeks
gestation, those who also provided a less favorable expectation of assigned treatment
(<3.75) were most likely to experience postpartum depression. Lastly, those who scored
below 11 on the HRSD17 at 36 weeks gestation, yet endorsed greater levels of childhood
emotional abuse (≥ 15), were more likely to experience postpartum depression. These
findings demonstrate the importance of addressing depressive symptoms during
pregnancy as well as provide evidence of increased risk for postpartum symptoms
associated with negative client expectations of treatment and childhood emotional abuse.
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The best predictor of clinically significant postpartum symptomatology was
experiencing HRSD17 ≥ 11 (mild depression) at the end of pregnancy. This finding is
consistent with the literature in which previous studies have found that many cases of
postpartum depression, up to 40%, are preceded by depression during pregnancy
(Milgrom et al., 2007; Verkerk et al., 2003). The implication is that it is important to
target women who are at risk for postnatal depression and begin screening during mid-tolate pregnancy.
It is well documented that patients’ expectations of treatment effectiveness can
have a powerful influence on outcome in terms of predicting full recovery and reduction
of depression symptoms post-treatment (Sotsky et al., 1991). Also, because of their
potency, expectations have been conceptualized as a “common factor” of intervention
(Frank & Frank, 1991). In exploring predictors of postpartum depressive symptoms,
expectancy played an influential role, as participants with HRSD17 ≥ 11 (mild depression)
during late pregnancy and with low expectations of their assigned treatment were at
greatest risk for experiencing postpartum depression. This suggests that expectations
may not only influence treatment outcome, but may result in enduring depressive
symptoms through pregnancy and into the postpartum. Thus when considering viable
treatment options for high-risk women during pregnancy, it will be important to promote
favorable expectations of the treatment to increase the likelihood of success in the
postpartum.
Interestingly, among women who did not exhibit increased levels of depression
symptomatology during late pregnancy, the findings provided evidence of increased risk
for postpartum depression associated with a history of childhood emotional abuse.
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Literature on predictors of postpartum depression have yielded mixed results when
examining the effect of exposure to abuse in childhood and its impact on postpartum
depression. Furthermore, it is not clear that these studies have separated forms of abuse,
whether sexual, physical or emotional. There have been a number of studies indicating
that emotional abuse is associated with increased levels of depression (Mullen, Martin,
Anderson, Romans, & Herbison, 1996; Rich, Gingerich, & Rosen, 1997; Spertus,
Yehuda, Wong, Halligan, & Seremetis, 2003). Additionally, there is emerging evidence
that history of childhood emotional abuse predicts depressive symptomatology even
when controlling for other types of abuse, suggesting it is more severe than overt forms
of abuse and has implications for women’s mental health (Spertus et al., 2003). The
mechanism by which this is operating in the current study is unclear; however, it may be
that the psychological and social adjustments associated with childbirth and parenthood
activate preexisting negative beliefs and fears. Given the current finding, future studies
might further evaluate the impact of childhood trauma and the role of emotional abuse,
particularly in women who otherwise do not appear to be at risk for postpartum
depression.
Exploratory analyses were also completed to identify characteristics of women
who were at risk for experiencing MDD during postpartum (meeting SCID criteria). The
findings revealed that women who stopped taking an antidepressant medication after
conception were most likely to experience MDD during postpartum. Furthermore,
women who had not taken an antidepressant early in pregnancy, yet scored at or above 25
on their intake HRSD17 (very severe range) were also more likely to experience MDD
during postpartum.
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These findings demonstrate that women with recent and severe depressive
symptomatology were at greatest risk of meeting criteria for MDD during the postpartum
phase. In this analysis, the best predictor was stopping antidepressant medication
subsequent to conception. This finding is consistent with research by Cohen et al.
(2006) in which he reported a five times higher rate estimate of relapse among pregnant
women who discontinued antidepressant medication. Furthermore, women enduring
higher rates of depressive symptomatology at intake, in the very severe range, were more
likely to experience MDD postpartum. Again, this finding is consistent with the
literature which indicates that high depressive symptomatology during mid-pregnancy
(mean gestation age for the current study was 20.58 weeks) is one of the largest risk
factors predicting postpartum depression (Verkerk et al., 2003) and that depressionrelated variables at the time of acute treatment appear to be the most reliable predictors of
long-term outcome (Szadoczky, Rozsa, Zambori, & Furedi, 2004).
Taken together, the findings from the second ROC analysis support previous
research and suggest that women who appear at high-risk during pregnancy, due to recent
antidepressant use and significant depression symptomatology, are at increased risk for
MDD postpartum. In turn, these findings highlight the dilemma women face who are
taking antidepressants or who are severely depressed, particularly given the risks
associated with antidepressant use during pregnancy. Thus, it will remain important for
further research to continue to investigate both the short and long term effects of
antidepressant treatments as well as continue to focus on the development of efficacious
alternative treatments in this population.
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Finally, it is important to emphasize that the ROC analysis is a method for
generating hypotheses rather than testing hypotheses and that the number of participants
in these analyses were small. Therefore, replication of the above listed findings should
be tested in other samples before the predictor variables and cut-points identified in this
study can be adopted as recommendations for clinical decision making. Future analyses
might also attempt to explore predictors of postpartum depression with a larger sample.
Though the current findings are consistent with the literature, they should be viewed as
providing preliminary guidelines for identifying patients at risk for experiencing
postpartum depression.
Limitations and Directions for Future Research
Generalizability
Several sample characteristics may limit the generalizability of the results. These
include the high education and socioeconomic status as well as the predominance of
Caucasians (66.9%). This may have impacted the results twofold in that (1) the data may
not generalize to minority populations, and (2) participants in this study may have had
access to resources which served to reduce stress following childbirth. Additionally, the
exclusion criteria for this study included comorbid psychiatric conditions and medical
disorders. The results may not generalize to pregnant women with other comorbid
mental health conditions or to those with severe depression which might include
psychotic features or suicide plans. Excluding participants with comorbid Axis I and
Axis II disorders may have reduced complications in adherence to and potential response
to treatment, which might also be considered when reflecting on the current study results.
Finally, follow-up data was not obtained for all randomized participants in the study and
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although there were few differences between those who completed follow-up and those
who did not, further replication is needed to ensure generalizability of the results. Future
research might focus efforts on including a more diverse participant population both in
terms of ethnic background and socioeconomic status, as well as including a more diverse
psychiatric population particularly given the high rates of comorbid psychiatric
conditions among individuals diagnosed with major depression.
Measurement
Several measurement concerns must be considered when weighing the current
results. First, the majority of follow-up HRSD17 interviews were completed over the
phone as opposed to in person. Great attempts were made to reach participants and as a
result, few were lost to follow-up. However, it may be more difficult to determine certain
behavioral aspects of depression when the assessment is not completed in person
resulting in a less sensitive measurement. Conversely, there is an emerging body of
evidence supporting telemedicine interventions which suggests that face-to-face contact
may not be necessary to complete a competent assessment of mood functioning.
Additionally, the majority of BDI-II follow-ups were mailed to participants. As a result,
the number of completed BDI-IIs at each postpartum time point is lower than the number
of HRSD17 assessments completed. Despite this, there was no evidence of differences in
patterns of response on the HRSD17 when examining those who returned BDI-IIs
compared to those who did not. Again, while efforts were made to encourage
participants to complete the BDI-II, the number returned was likely impacted by the
medium used for measurement.
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A second limitation of the current study was the lack of a continuous timeline of
depression symptoms over the course of the postpartum phase. Participants were
assessed at three time points (ten weeks, six months, and nine months postpartum). Data
was not available for the periods of time falling between these assessments. It is possible
periods of depressive symptomatology may have been missed, and perhaps rates of
postpartum depression are lower, because of the frequency of mood assessments or the
incidence of depression peaked at a time not measured in this study.
Third, a potential confound to the current results was the influence of continuation
sessions on the maintenance of response to treatment. Attempts were made to control for
continuation sessions, both during pregnancy and postpartum, by including these sessions
as a covariate in the major statistical analyses and when doing so, the results held.
Controlling for continuation sessions was not meant to suggest that continuation sessions
are not effective or do not play a role in maintaining either a treatment or response effect.
This was not specifically tested; rather, in the current study it was demonstrated that
response to treatment can have an impact in the postpartum above and beyond the impact
of continuation. Further research might look specifically at the role continuation sessions
play in preventing further reemergence of mood symptoms postpartum following
completion of the acute phase of treatment.
Emphasis on Response Status
The main analyses for the current study focused on response status to the acute
phase of treatment. Several limitations are associated with this categorization. Although
conclusions can be made about the role of response status on depressive symptoms
throughout the postpartum, these conclusions are complicated by the differing treatments
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participants received within the current study. Because the study did not focus
specifically on treatment effects, less conclusive findings can be made with regard to the
impact of treatment itself on the postpartum presentation. Post-hoc analyses in the
current study, limited solely to responders, provided initial evidence supporting the
impact of acupuncture specific for depression on maintaining change and improvement
postpartum. However, limiting analyses solely to responders, reduced the sample size to
a smaller number which may have decreased power. While the current research builds
upon the findings of Manber et al. (2004; 2010), conclusive statements regarding
treatment effects and in relation to enduring effects of acupuncture must be cautiously
interpreted. Future research might explore more specifically the role of acupuncture in
both treating and preventing postpartum depressive symptoms and focus on including
larger sample sizes.
Finally, in the current study, analyses comparing treatments collapsed the control
groups to include both massage and acupuncture not specific to depression (NPEC). It
cannot be assumed that the placebo response for massage and control acupuncture are the
same. Furthermore, while attempts were made to double blind acupuncturists, the
massage condition was unblinded. The massage group may have generated a downward
or upward effect on the control mean. In fact, the massage and NSPEC groups differed in
their depression score means such that the massage group tended to fare better,
potentially demonstrating a therapeutic effect, which made it more difficult to find a
treatment effect when comparing SPEC to the combined control groups.
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Implications for Clinical Practice and Conclusion
The long term consequences of postpartum depression suggest that preventative
approaches are warranted. The implications of the current study results in relation to
potential prevention of postpartum depression are twofold: (1) identify and target highrisk women during pregnancy, and (2) successful treatment during pregnancy may have
enduring effects into the postpartum phase. Therefore, the current results provide
information related to both characteristics placing women at greatest risk as well as the
timing of greatest risk.
In the current study, women were most at risk for experiencing postpartum
depressive symptomatology based on the level of their depressive symptoms during
pregnancy. This finding is consistent with the literature and suggests that evaluating
indicated interventions (e.g., targeting women with existing symptoms or early diagnosis
of depression during pregnancy) may be a more fruitful approach to preventing
postpartum depression rather than waiting until symptoms emerge postpartum. In fact,
pregnancy provides an ideal opportunity for prevention because its onset is preceded by a
clear marker (giving birth), the period of risk for illness onset is well-defined, and a highrisk sample of mothers can be identified. Additionally, pregnant women may be
unusually open to making changes to improve their mental health before their baby is
born (Cowan & Cowan, 2000). Therefore, emphasis on screening and identifying women
at high-risk during pregnancy are critical components for prevention measures.
Additionally, once a high-risk group is identified, interventions might be targeted
at them and implemented during pregnancy. The current findings are aligned with
emerging research which suggests that successful treatment during pregnancy may have a
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lasting effect into the postpartum phase. In the context of the current study, alternative
treatments were utilized; and, while response to any of the study treatments resulted in an
enduring effect postpartum, preliminary evidence suggested women treated with
acupuncture specifically tailored for depression experienced the most enduring effect.
Eliciting from women their preferred choice of treatment, if determined to be high-risk,
may also be beneficial given response may be equally important as treatment assignment.
Future studies might expand upon the emerging body of research which demonstrates
enduring response to treatment postpartum, following implementation during pregnancy.
Given the deleterious costs of postpartum depression to individuals and society,
prevention and treatment remain concerns. Efforts have begun to focus on better
understanding the illness; however, there remains a significant lack of substantial highquality research in this area (Wisner et al., 2006). Continued focus on both increased
surveillance of postpartum depression and better implementation of preventative and
treatment options for childbearing women is needed. Future research might continue to
focus on addressing critical questions related to the course and treatment of maternal
depression, which in turn might inform approaches of preventive interventions with
pregnant and postpartum women.

APPENDIX A
PERINATAL SURVEY
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Perinatal Survey
IN: ______ ID#:________

Date: ____________

Pregnancy Information
Date of first day of last menstrual period (LMP): ________________
How certain are you of this LMP?______________________
Estimated number of weeks of pregnancy _________
Due Date: ___________
Due Date is based on:

LMP
Ultrasound: date of ultrasound_______________
Conception date
Other _______________

Weight before pregnancy _________________

SECTION I - Background Information
Date of your birth: _________ (mm/dd/yyyy)

(please make sure the year is the year of birth)
1) Living arrangement

Live with husband
Not married but live with a partner
Live without a partner but with other adults
specify relationship of others to you
_________________________________________________
__________________________________________________
I am the only adult in my household
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We must report to the government, which funds this study, a summary of both ethnicity and
race of participants in our study. Therefore, please answer BOTH questions #2 (Ethnicity)
and #3 (Racial Background) though it may seem redundant.
2) Select Ethnicity:

Hispanic or Latino

or

3) Select Racial Background:
American Indian/ Alaska Native
Native Hawaiian or Other Pacific Islander
Black or African American

Not Hispanic or Latino

Asian
White
Other ________________

4) Health Insurance
a) Do you have a general health insurance plan?
Yes

No

b) Do you have any insurance coverage of mental health?
Yes

No

c) Do you have coverage of prenatal care?
Yes

No

d) Do you have insurance coverage of post-partum care? (For at least 2 months after delivery)
Yes

No

5) Transportation
When it comes to getting transportation to clinic/study appointments would you say that:
Transportation is not a problem.
You will usually be able to get transportation.
You might have occasional trouble getting transportation.
Transportation will always be a problem.

Education & employment
6) How many years of formal education have you completed?
No High School
Some High School
High School Diploma

Some College
College Degree
Additional Education – Please specify ________________
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7) What is your usual profession? ____________________________________
8) Present employment status:
Working full-time
Working part-time
Homemaker
Unemployed

Student
Disabled
On Leave because of pregnancy
On Leave for reasons other than pregnancy

Other ___________________________________________________
9) From all sources of income, including your own, what is the total combined income of all
people you live with?
a)

Less than $10,000
$10,000 to $20,000
$20,000 to $30,000

$30,000 to $40,000
$40,000 to $50,000
$50,000 to $60,000

$70,000 to $100,000
Over $100,000

b) How many people are supported by this income? __________
c) Do you receive SSI or child support?
Yes

No

SECTION II - Pregnancy
1) a. Was this pregnancy planned?
Yes

No

b. If not, were you planning to have children ever?
Yes

No

2) a. Does the father of the baby live with you?
Yes

No

b. If not, do you live with a partner committed to parenting the child with you?
Yes

No

3) Is the father of the baby involved?
Yes

No
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4) Please check all that apply regarding the involvement of the father of the baby.
The father of the baby:
a. Provides some financial support
Yes

No

b. Has excitement and interest in having this child
Yes

No

c. Understands my emotional needs related to this pregnancy
Yes

No

4) The numbers on the following line represent different degrees of happiness in your
relationship. The middle point, "happy", represents the degree of happiness of most
relationships. Please circle the number which best describes the degree of happiness,
all things considered, of your relationship.
0

1

2

3

4

5

6

Extremely

Fairly

A Little

Happy

Very

Extremely

Perfectly

Unhappy

Unhappy

Unhappy

Happy

Happy

Happy

5) Do you have friends or family members who will be able to help with the physical
care of your baby after delivery?
Yes

No

If yes, specify how many people will be able to assist you ______
6) Do you have friends or family members who will be available to you for emotional
support after you deliver your baby?
Yes

No

If yes, specify how many people will provide emotional support ______
7) Are you attending or planning to attend childbirth classes?
Yes

No

If yes, please specify type of class _________________
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8) Are you attending or planning to attend parenting classes?
Yes

No

9) Are you taking vitamins daily or almost daily?
Yes

No

10) How do you plan to feed the baby?
Bottle (formula)

Breast feed

Both bottle and breast feed

11) Have you experienced any of the following in association with this pregnancy?
Nausea
Vomiting
Heartburn
Constipation
Food cravings (What do you crave? __________________)
12) Please indicate below the type of delivery and pain control that is anticipated?
a) Type of delivery
b) Type of pain control

Vaginal
None

C-section
Epidural

Other _____________

SECTION III – Depression
Depression and Nausea Timeline
Month/year depression began: ________
1. When did this depressive episode begin in relation to the present pregnancy?
Before current pregnancy

During current pregnancy

2. Do you believe that being pregnant has affected the present depressive episode?
No, pregnancy had no impact on my depression - the two are independent
Yes, pregnancy made it somewhat better
Yes, pregnancy made it somewhat worse
Yes, pregnancy is the cause of my depression
3. Have you experience nausea during this pregnancy?

Yes

If you answered yes to question 3 then please continue. If No, then
skip to SECTION IV.

No
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3b. Month/year your nausea began? ____________
3c. Please check the box that applies best:
Nausea preceded depression
Nausea began after the onset of depression
Nausea and depression emerged simultaneously
4a. What role do you think nausea has played in causing your depression?
Nausea is the primary cause of my depression
Nausea is partially responsible for my depression
My depression is not related to nausea
4b. If you think nausea did play a role in causing the onset of your depression, please check the
statement that best describes your experience at that time:
Unable to keep meals, or vomited more than once a day
Vomited once a day
Nausea was present most of the day, but no vomiting
Nausea was present, but not all day
5. What relationship, if any, have you noticed between the experience of nausea and depressed
mood?
Strong relationship

Minimal relationship

No relationship

6. Do you experience nausea at this point in your pregnancy?
No
If no, when did your nausea end _____________ (month/year)
Yes

If yes, please check the box that applies best:
Unable to keep meals, or vomit more than once a day
Vomit once a day
Nausea present most of the day, but no vomiting
Nausea present, but not all day

SECTION IV – Hospitalizations and Medications
1. List all your hospitalizations stating specific type of illness/surgery/hospitalization.
Please be specific.
____________________________________________________________ Year_________
____________________________________________________________ Year_________
____________________________________________________________ Year_________
____________________________________________________________ Year_________
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2. What prescription medications are you presently taking? List name, dosage, and how often
you take each medication.
Name

Dosage

Frequency

Comments ___________________________________________________________________
____________________________________________________________________________
3. What non-prescription medications do you presently take? For example – herbs, laxatives,
diet pills, vitamins, antacids or cold remedies. List name, dosage, and how often you take each.
Name

Dosage

Frequency

Comments ___________________________________________________________________
____________________________________________________________________________

SECTION V - Smoking Habits
1. Do you smoke now?

Yes If so, how much? _____________________________
No

2. Have you quit recently?

Yes

No

3. Did you stop because of pregnancy?
applicable

Yes

No

If so, when?

before pregnancy (date ___________)
during pregnancy

not
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SECTION VI – Health Maintenance
For each of the statements below please indicate how often you do each of the following.
In the left column, indicate frequency prior to this pregnancy. In the right column,
indicate frequency during this pregnancy.

1) use seat belt?

2) comply with a routine
dental check up schedule
(every 6-12 months)?
3) wear a helmet when
riding a bike or
motorcycle?
4) have sexual partners use
condoms?
5) eat nutritional meals

6) get enough rest

7) drink and drive

8) exercise for at least 20
minutes at least 3 times a
week?
9) take vitamins / minerals

Before pregnancy

During pregnancy

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable

always
usually
rarely
never
not applicable
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Section VII Acupuncture/Massage Treatments:
1) Have you ever received acupuncture treatment in the past?
Yes

No

If Yes,
When was your last acupuncture treatment (month/year)?

What was the purpose of the treatment?
Was it helpful?

very much

somewhat

not at all

2) Have you received massage from a professional massage therapist before?
Yes

No

If Yes,
When was your last massage session?
If it was part of a series of massage sessionsHow many sessions did you have? _______________
How often did you have them (eg. once/week, twice/week)? ______________

Did massage help your mood?

very much

somewhat

not at all

3) The answers to the following questions will not determine which group you will
be assigned to in the study. This is determined by a completely randomized system.
We would just like to know what your preference would be.
a. Do you have a preference for receiving acupuncture or massage as your
treatment in the study?
Acupuncture

Massage

b. Which do you think would be more helpful in treating your depression?
Acupuncture

Massage
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